| Year |
Citation |
Score |
| 2021 |
Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, Özcan M, Hong X, Zhu J, Jin J, Belada D, Bergua JM, Piazza F, Mócikova H, Molinari AL, ... ... Czuczman M, et al. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001366. PMID 33621109 DOI: 10.1200/JCO.20.01366 |
0.304 |
|
| 2020 |
Sohani AR, Maurer MJ, Giri S, Pitcher B, Chadburn A, Said JW, Bartlett NL, Czuczman MS, Martin P, Rosenbaum CA, Jung SH, Leonard JP, Cheson BD, Hsi ED. Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. The American Journal of Surgical Pathology. PMID 33136585 DOI: 10.1097/PAS.0000000000001609 |
0.379 |
|
| 2019 |
Ogasawara K, Newhall K, Maxwell SE, Dell'Aringa J, Komashko V, Kilavuz N, Delarue R, Czuczman M, Sternas L, Rose S, Beach CL, Novick S, Zhou S, Palmisano M, Li Y. Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies. Clinical Pharmacokinetics. PMID 31332669 DOI: 10.1007/S40262-019-00804-X |
0.353 |
|
| 2019 |
Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-López AJ, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Seminars in Oncology. 29: 36-40. PMID 28140090 DOI: 10.1053/sonc.2002.30152 |
0.426 |
|
| 2019 |
Julia E, Fowler NH, Bachy E, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas R, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, ... ... Czuczman M, et al. Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial Blood. 134: 1524-1524. DOI: 10.1182/Blood-2019-129024 |
0.405 |
|
| 2019 |
Casulo C, Santoro A, Ando K, Le Gouill S, Ruan J, Radford J, Arcaini L, Pinto A, Bouabdallah R, Izutsu K, Rule S, Munoz J, Casadebaig M, Fox B, Rettby N, ... ... Czuczman M, et al. Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial Blood. 134: 5320-5320. DOI: 10.1182/Blood-2019-124102 |
0.451 |
|
| 2019 |
Chiappella A, Witzig TE, Cocks K, Greenwood M, Williams A, Scott DW, Gascoyne RD, Yamamoto K, Jurczak W, Özcan M, Belada D, Burgues JMB, Piazza F, Visco C, Musuraca G, ... ... Czuczman M, et al. Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study Blood. 134: 3475-3475. DOI: 10.1182/Blood-2019-123948 |
0.399 |
|
| 2019 |
Wenzl K, Ortiz M, Stong N, Huang CC, Maurer MJ, Towfic F, Hagner PR, Nikbakht H, Stokes M, Lata S, Kamalakaran S, Mavrommatis K, Trotter M, King RL, Link BK, ... ... Czuczman M, et al. Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma Blood. 134: 919-919. DOI: 10.1182/Blood-2019-123694 |
0.368 |
|
| 2019 |
Nowakowski G, Chiappella A, Hong F, Gascoyne RD, Scott DW, Macon WR, King RL, Amengual JE, Little RF, Leonard JP, Friedberg JW, Kostakoglu L, Jurczak W, Yamamoto K, Czuczman M, et al. Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies Blood. 134: 4092-4092. DOI: 10.1182/Blood-2019-123083 |
0.415 |
|
| 2019 |
Ortiz M, Wenzl K, Stokes M, Huang CC, Maurer MJ, Towfic F, Hagner PR, Ratushny A, McConnell M, Danziger SA, Stong N, Lata S, Kamalakaran S, Mavrommatis K, Trotter M, ... ... Czuczman M, et al. Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse Blood. 134: 923-923. DOI: 10.1182/Blood-2019-122756 |
0.362 |
|
| 2019 |
Trněný M, Leonard JP, Zhang H, Nowakowski G, Izutsu K, Fowler NH, Thieblemont C, Zinzani PL, Kalambakas S, Czuczman M, Fustier P, Wu C, Gribben JG. Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) Blood. 134: 347-347. DOI: 10.1182/Blood-2019-122461 |
0.361 |
|
| 2019 |
Thieblemont C, Leonard J, Trneny M, Izutsu K, Fowler N, Hong X, Zhang H, Offner F, Scheliga A, Nowakowski G, Pinto A, Re F, Fogliatto L, Scheinberg P, Flinn I, ... ... Czuczman M, et al. PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA Hemasphere. 3: 577-578. DOI: 10.1097/01.HS9.0000563328.65533.4E |
0.318 |
|
| 2019 |
Gribben J, Trneny M, Izutsu K, Fowler N, Hong X, Zhang H, Offner F, Scheliga A, Nowakowski G, Pinto A, Re F, Fogliatto L, Scheinberg P, Flinn I, Moreira C, ... Czuczman M, et al. PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT) Hemasphere. 3: 571-572. DOI: 10.1097/01.HS9.0000563288.81673.B1 |
0.35 |
|
| 2019 |
Leonard J, Trneny M, Izutsu K, Fowler N, Hong X, Zhang H, Offner F, Scheliga A, Nowakowski G, Pinto A, Re F, Fogliatto L, Scheinberg P, Flinn I, Moreira C, ... Czuczman M, et al. Augment Phase Iii Study: Lenalidomide/Rituximab (R2) Improved Efficacy Over Rituximab/Placebo In Relapsed/Refractory Follicular Patients Irrespective Of Pod24 Status Hematological Oncology. 37: 114-115. DOI: 10.1002/Hon.75_2629 |
0.394 |
|
| 2019 |
Vitolo U, Witzig TE, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, Özcan M, Hong X, Zhu J, Jin J, Belada D, Bergua JM, Piazza F, Mócikova H, Molinari AL, ... ... Czuczman M, et al. ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma Hematological Oncology. 37: 36-37. DOI: 10.1002/Hon.5_2629 |
0.342 |
|
| 2019 |
Gribben J, Trneny M, Izutsu K, Fowler NH, Hong X, Zhang H, Offner F, Scheliga A, Nowakowski G, Pinto A, Re F, Fogliatto L, Scheinberg P, Flinn I, Moreira C, ... Czuczman M, et al. Augment: Relapsed/Refractory Indolent Nhl Patients Were More Sensitive To Next Treatment Following Lenalidomide/Rituximab (R2) Than Rituximab/Placebo Hematological Oncology. 37: 227-229. DOI: 10.1002/Hon.42_2630 |
0.409 |
|
| 2019 |
Thieblemont C, Leonard J, Trneny M, Izutsu K, Fowler N, Hong X, Zhang H, Offner F, Scheliga A, Nowakowski G, Pinto A, Re F, Fogliatto L, Scheinberg P, Flinn I, ... ... Czuczman M, et al. Post Hoc Analyses Of Patients With Relapsed/Refractory Marginal Zone Lymphoma Who Received Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo (Augment) Hematological Oncology. 37: 226-227. DOI: 10.1002/Hon.41_2630 |
0.447 |
|
| 2018 |
Lansigan F, Barak I, Pitcher B, Jung SH, Cheson BD, Czuczman M, Martin P, Hsi E, Schöder H, Smith S, Bartlett NL, Leonard JP, Blum KA. The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. Cancer Medicine. PMID 30575311 DOI: 10.1002/Cam4.1918 |
0.458 |
|
| 2018 |
Gu JJ, Singh A, Xue K, Mavis C, Barth M, Yanamadala V, Lenz P, Grau M, Lenz G, Czuczman MS, Hernandez-Ilizaliturri FJ. Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. Oncotarget. 9: 4020-4033. PMID 29423101 DOI: 10.18632/Oncotarget.23425 |
0.457 |
|
| 2017 |
Torka P, Patel P, Tan W, Wilding G, Bhat SA, Czuczman MS, Lee KP, Deeb G, Neppalli V, Mavis C, Wallace P, Hernandez-Ilizaliturri FJ. A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. PMID 29233743 DOI: 10.1016/J.Clml.2017.09.003 |
0.486 |
|
| 2017 |
Czuczman MS, Trněný M, Davies A, Rule SA, Linton K, Wagner-Johnston N, Gascoyne RD, Slack G, Brousset P, Eberhard DA, Hernandez-Ilizaliturri FJ, Salles G, Witzig TE, Zinzani PL, Wright GW, et al. A Phase 2/3 Multicenter, Randomized, Open-Label Study of Lenalidomide vs Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28381416 DOI: 10.1158/1078-0432.Ccr-16-2818 |
0.437 |
|
| 2016 |
Gu JJ, Kaufman GP, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ. Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells. Oncotarget. PMID 28055975 DOI: 10.18632/Oncotarget.14405 |
0.444 |
|
| 2016 |
Zhou Z, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, Vanderplas A, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson MM, Zelenetz AD, Niland J, Friedberg JW, et al. High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 1274-1281. PMID 27697981 DOI: 10.6004/Jnccn.2016.0136 |
0.354 |
|
| 2016 |
Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, Smith SM, Czuczman M, Davids MS, Levine E, Lewis LD, Smith SE, Bartlett NL, Leonard JP, Cheson BD. Phase I trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood. PMID 27697771 DOI: 10.1182/Blood-2016-06-718106 |
0.435 |
|
| 2016 |
Lamonica D, Graf DA, Munteanu MC, Czuczman MS. 18F-Fluorodeoxyglucose (FDG) PET for Measurement of Response and Prediction of Outcome to Relapsed/Refractory Mantle Cell Lymphoma (MCL) Therapy with Bendamustine-Rituximab(BR). Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27469362 DOI: 10.2967/Jnumed.116.173542 |
0.375 |
|
| 2016 |
Xue K, Gu JJ, Zhang Q, Liu X, Wang J, Li XQ, Luo J, Hernandez-Ilizaliturri FJ, Fernandez SF, Czuczman MS, Cao J, Hong X, Guo Y. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial. Oncotarget. PMID 27081036 DOI: 10.18632/Oncotarget.8685 |
0.475 |
|
| 2016 |
Lansigan F, Barak I, Pitcher BN, Jung S, Cheson B, Czuczman MS, Grant BW, Martin P, Hsi ED, Schoder H, Smith SE, Bartlett NL, Leonard JP, Blum K. Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance) Blood. 128: 2953-2953. DOI: 10.1182/Blood.V128.22.2953.2953 |
0.463 |
|
| 2015 |
Czuczman NM, Barth MJ, Gu J, Neppalli V, Mavis C, Frys SE, Hu Q, Liu S, Klener P, Vockova P, Czuczman MS, Hernandez-Ilizaliturri FJ. Pevonedistat, a NEDD8 activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo. Blood. PMID 26675347 DOI: 10.1182/blood-2015-04-640920 |
0.366 |
|
| 2015 |
Awasthi A, Ayello J, Van de Ven C, Elmacken M, Sabulski A, Barth MJ, Czuczman MS, Islam H, Klein C, Cairo MS. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL. British Journal of Haematology. PMID 26471982 DOI: 10.1111/Bjh.13764 |
0.378 |
|
| 2015 |
Czuczman MS, Goy A, Lamonica D, Graf DA, Munteanu MC, van der Jagt RH. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Annals of Hematology. 94: 2025-32. PMID 26411584 DOI: 10.1007/S00277-015-2478-9 |
0.461 |
|
| 2015 |
Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. Journal of Cancer Research and Clinical Oncology. PMID 26314218 DOI: 10.1007/S00432-015-2026-Y |
0.474 |
|
| 2015 |
Leonard JP, Jung SH, Johnson J, Pitcher BN, Bartlett NL, Blum KA, Czuczman M, Giguere JK, Cheson BD. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26304886 DOI: 10.1200/Jco.2014.59.9258 |
0.458 |
|
| 2015 |
Nowakowski GS, Czuczman MS. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection? American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. e449-57. PMID 25993209 DOI: 10.14694/EdBook_AM.2015.35.e449 |
0.423 |
|
| 2015 |
Barth MJ, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ. Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in pre-clinical models of mantle cell lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25964296 DOI: 10.1158/1078-0432.Ccr-15-0056 |
0.539 |
|
| 2015 |
Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. The Lancet. Oncology. 16: 704-15. PMID 25925619 DOI: 10.1016/S1470-2045(15)70128-2 |
0.478 |
|
| 2015 |
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 326-62. PMID 25736010 DOI: 10.6004/Jnccn.2015.0045 |
0.467 |
|
| 2015 |
Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, Vitolo U, Fowler N, Czuczman MS. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1667-77. PMID 25712458 DOI: 10.1093/Annonc/Mdv102 |
0.527 |
|
| 2015 |
Frys S, Simons Z, Hu Q, Barth MJ, Gu JJ, Mavis C, Skitzki J, Song L, Czuczman MS, Hernandez-Ilizaliturri FJ. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. British Journal of Haematology. 169: 506-19. PMID 25712263 DOI: 10.1111/Bjh.13318 |
0.502 |
|
| 2015 |
Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dörken B, Chu YW, Chen AI, Lebovic D, Salles GA, ... Czuczman MS, et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia. 29: 1578-86. PMID 25708834 DOI: 10.1038/Leu.2015.48 |
0.412 |
|
| 2015 |
Czuczman MS, Kahanic S, Forero A, Davis G, Munteanu M, Van Den Neste E, Offner F, Bron D, Quick D, Fowler N. Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma. Annals of Hematology. 94: 633-41. PMID 25630297 DOI: 10.1007/S00277-014-2269-8 |
0.498 |
|
| 2015 |
Chu Y, Hochberg J, Yahr A, Ayello J, van de Ven C, Barth M, Czuczman M, Cairo MS. Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice. Cancer Immunology Research. 3: 333-44. PMID 25492700 DOI: 10.1158/2326-6066.Cir-14-0114 |
0.449 |
|
| 2015 |
Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson M, Nademanee AP, Zelenetz A, LaCasce AS, Rodriguez MA. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 121: 1032-9. PMID 25492236 DOI: 10.1002/Cncr.29113 |
0.398 |
|
| 2015 |
Zhang Q, Gu JJ, Mavis C, Guo Y, Hernandez-Ilizaliturri FJ, Czuczman MS. Carfilzomib, a second-generation proteasome inhibitor, to enhance the activity of ibrutinib in rituximab-chemotherapy sensitive or resistant B-cell lymphoma cell lines and primary patient samples. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E19524 |
0.473 |
|
| 2015 |
Patel PP, Gu JJ, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ. Metformin enhances the activity of rituximab in B-cell lymphoma pre-clinical models. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E19513 |
0.482 |
|
| 2015 |
Torka P, Hernandez-Ilizaliturri FJ, Bhat SA, Czuczman MS, Basra P, Kuvshinoff BW, Deeb G, Skitzki JJ, Neppalli V. Impact of clinical parameters on surgical outcomes in patients with hematological disorders undergoing splenectomy. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E17689 |
0.313 |
|
| 2015 |
Runckel KL, Mavis C, Skitzki J, Gu JJ, Hernandez-Ilizaliturri FJ, Czuczman MS. Targeting the X-Linked Inhibitor of Apoptosis Protein (XIAP) Can Promote Tumor Cell Death, and Increase the Cytotoxic Effects of Chemotherapy Agents in in Vitro and In Vivo Models of Rituximab-Resistant Lymphoma Blood. 126: 590-590. DOI: 10.1182/Blood.V126.23.590.590 |
0.511 |
|
| 2015 |
Gu JJ, Zhang Q, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ. Metformin Induces p53-Dependent Mitochondrial Stress in Therapy-Sensitive and -Resistant Lymphoma Pre-Clinical Model and Primary Patients Sample with B-Cell Non-Hodgkin Lymphoma (NHL) Blood. 126: 4008-4008. DOI: 10.1182/Blood.V126.23.4008.4008 |
0.486 |
|
| 2015 |
Zhang Q, Gu JJ, Guo Y, Klos J, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ. Dual Inhibition of PKC Delta By Carfilzomib (CFZ) and Ibrutinib Results in Synergistic Activity in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Pre-Clinical Models and in Primary Tumor Cells Isolated from B-Cell Lymphoma Patients Blood. 126: 4006-4006. DOI: 10.1182/Blood.V126.23.4006.4006 |
0.531 |
|
| 2015 |
Gu JJ, Zhang Q, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ. Palbociclib (PD-0332991), a Potent Selective CDK4/6 Inhibitor, Overcomes Therapy-Resistant and Sensitizes Diffuse Large B-Cell Lymphoma Pre-Clinical Models to Chemo-Reagents Blood. 126: 3997-3997. DOI: 10.1182/Blood.V126.23.3997.3997 |
0.493 |
|
| 2015 |
Torka P, Patel PP, Tan W, Wilding G, Bhat SA, Czuczman MS, Lee KP, Deeb G, Neppalli VT, Mavis C, Hernandez-Ilizaliturri FJ. Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study Blood. 126: 3975-3975. DOI: 10.1182/Blood.V126.23.3975.3975 |
0.573 |
|
| 2015 |
Kaplan LD, Jung S, Stock W, Bartlett NL, Pitcher B, Byrd JC, Blum KA, LaCasce AS, Fulton N, Hsi ED, Hurd DD, Czuczman M, Leonard JP, Cheson BD. Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403 Blood. 126: 337-337. DOI: 10.1182/Blood.V126.23.337.337 |
0.368 |
|
| 2015 |
Sohani AR, Pitcher B, Chadburn A, Said JW, Martin P, Czuczman MS, Bartlett NL, Rosenbaum CA, Leonard JP, Cheson BD, Hsi ED. Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401) Blood. 126: 334-334. DOI: 10.1182/Blood.V126.23.334.334 |
0.415 |
|
| 2015 |
Gu JJ, Zhang Q, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ. JQ1, a Potent c-MYC Inhibitor Overcomes Rituximab-Chemotherapy Resistance in Lymphoma Pre-Clinical Models Blood. 126: 2761-2761. DOI: 10.1182/Blood.V126.23.2761.2761 |
0.519 |
|
| 2015 |
Torka P, Patel P, Tan W, Wilding G, Mavis C, Deeb G, Lee K, Bhat S, Czuczman M, Hernandez-Ilizaliturri FJ. Peg-filgrastim potentiates rituximab in patients with indolent lymphomas: results of a phase II study Clinical Lymphoma Myeloma and Leukemia. 15: S72. DOI: 10.1016/J.Clml.2015.07.146 |
0.336 |
|
| 2014 |
Mylam KJ, Kostakoglu L, Hutchings M, Coleman M, Lamonica D, Czuczman MS, Diehl LF, Nielsen AL, Jensen P, Loft A, Hendel HW, Iyer V, Leppä S, Jyrkkiö S, Holte H, et al. (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. Leukemia & Lymphoma. 1-8. PMID 25330442 DOI: 10.3109/10428194.2014.975800 |
0.328 |
|
| 2014 |
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, et al. Non-Hodgkin's lymphomas, version 4.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 1282-303. PMID 25190696 DOI: 10.6004/Jnccn.2014.0125 |
0.463 |
|
| 2014 |
Vaidyanathan G, Czuczman MS. Follicular lymphoma grade 3: review and updates. Clinical Lymphoma, Myeloma & Leukemia. 14: 431-5. PMID 25066038 DOI: 10.1016/J.Clml.2014.04.008 |
0.37 |
|
| 2014 |
Du J, Lopez-Verges S, Pitcher BN, Johnson J, Jung SH, Zhou L, Hsu K, Czuczman MS, Cheson B, Kaplan L, Lanier LL, Venstrom JM. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunology Research. 2: 878-89. PMID 24958280 DOI: 10.1158/2326-6066.Cir-13-0158 |
0.452 |
|
| 2014 |
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, et al. Non-Hodgkin's lymphomas, version 2.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 916-46. PMID 24925202 DOI: 10.6004/Jnccn.2014.0086 |
0.483 |
|
| 2014 |
Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson MM, Nademanee AP, Niland JC, Rodig SJ, Rodriguez MA, Zelenetz AD, LaCasce AS. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer. 120: 1993-9. PMID 24706502 DOI: 10.1002/Cncr.28676 |
0.414 |
|
| 2014 |
Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 123: 837-42. PMID 24264230 DOI: 10.1182/Blood-2013-09-524108 |
0.433 |
|
| 2014 |
Czuczman MS, Knecht H, Auer R, McKendrick JJ, Chua NS, Linton K, Collins G, Vos SD, Holes L, Abella E, Salles GA. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps8621 |
0.491 |
|
| 2014 |
Czuczman MS, Davies A, Linton KM, Wagner-Johnston N, Gascoyne RD, Eberhard DA, Salles G, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Repici J, Song D, Manzke O, Lewis ID. A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL Blood. 124: 628-628. DOI: 10.1182/Blood.V124.21.628.628 |
0.42 |
|
| 2014 |
Xue K, Gu J, Mavis C, Hernandez F, Czuczman MS, Guo Y. Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents Blood. 124: 5486-5486. DOI: 10.1182/Blood.V124.21.5486.5486 |
0.502 |
|
| 2014 |
Runckel KL, Skitzki J, Hernandez F, Czuczman MS. The SMAC Mimetic Lcl-161 Augments the in Vitro and in Vivo anti-Tumor Activity of Rituximab and Chemotherapy in Rituximab Relapse/Refractory Lymphoma Models Blood. 124: 3110-3110. DOI: 10.1182/Blood.V124.21.3110.3110 |
0.542 |
|
| 2014 |
Zhou Z, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, Vanderplas A, Abel GA, Rodriguez MA, Nademanee A, Kaminski M, Czuczman MS, Millenson MM, Niland J, Zelenetz AD, Friedberg JW, et al. High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender Blood. 124: 3046-3046. DOI: 10.1182/Blood.V124.21.3046.3046 |
0.41 |
|
| 2014 |
Xue K, Gu JJ, Zhang Q, Liu X, Wang J, Luo J, Hernandez-Ilizaliturri FJ, Fernandez SF, Czuczman MS, Cao J, Hong X, Guo Y. Elevated High Sensitivity Troponin T (HsTnT) during Front-Line Therapy with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone +/- Rituximab (CHOP+/-R) or Cyclophosphamide, Epirubicin, Vincristine and Prednisone +/- Rituximab (CEpOP+/-R) Correlates with a Decline in Left Ventricular Ejection Fraction (LVEF) in Patients with Aggressive B-Cell Lymphoma: Results from a Randomized Prospective Clinical Trial NCT00854568 Blood. 124: 3041-3041. DOI: 10.1182/Blood.V124.21.3041.3041 |
0.441 |
|
| 2014 |
Patel PP, Torka P, Neppalli VT, Deeb G, Sait SNJ, Block AW, Bhat SA, Czuczman MS, Hernandez-Ilizaliturri FJ. Intense Cytarabine-Based Chemo-Immunotherapy, Central Nervous System (CNS) Prophylaxis and Early High-Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS) in First Remission Are Associated with an Improved Clinical Outcome in Double-Hit (DHL)/Triple-Hit (THL) Diffuse Large B-Cell Lymphoma (DLBCL) Blood. 124: 3031-3031. DOI: 10.1182/Blood.V124.21.3031.3031 |
0.502 |
|
| 2014 |
Gu JJ, Yanamadala V, Singh A, Mavis C, Czuczman MS, Hernandez F. Metformin Affects the Proliferation Cell Nuclear Antigen (PCNA) and p21 Protein Interaction Resulting in Direct Anti-Tumor Activity and Enhances the Cytotoxic/Biological Effects of Chemotherapy Agents or Rituximab in Lymphoma in Vitro and in Vivo Pre-Clinical Models Blood. 124: 1781-1781. DOI: 10.1182/Blood.V124.21.1781.1781 |
0.527 |
|
| 2014 |
Torka P, Hernandez-Ilizaliturri FJ, Belliotti S, Mavis C, Gu J, Czuczman MS. Inhibition of Nuclear Factor Kappa B (NFkB)/Interferon Regulatory Factor 4 (IRF4) Signaling Pathway in Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) By Combining MLN4924, a Novel NEDD8 Activating Enzyme Inhibitor (NAE) and Ibrutinib Blood. 124: 1768-1768. DOI: 10.1182/Blood.V124.21.1768.1768 |
0.541 |
|
| 2014 |
Gu JJ, Singh A, Mavis C, Yanamadala V, Xue K, Grau M, Lenz P, Lenz G, Czuczman MS, Hernandez F. Up-Regulation of Hexokinase II (HK) Alters the Glucose Metabolism and Disrupts the Mitochondrial Potential in Aggressive B-Cell Lymphoma Contributing to Rituximab-Chemotherapy Resistance and Is a Clinically Relevant Target for Future Therapeutic Development Blood. 124: 1767-1767. DOI: 10.1182/Blood.V124.21.1767.1767 |
0.513 |
|
| 2014 |
Czuczman MS, Goy A, Lamonica D, Graf DA, Munteanu MC, Jagt RHvd. Bendamustine Plus Rituximab (BR) in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma of a Phase 2 Study: Multivariate Analysis and Updated Final Results By Subgroup Blood. 124: 1757-1757. DOI: 10.1182/Blood.V124.21.1757.1757 |
0.457 |
|
| 2014 |
Chu Y, Yahr A, Ayello J, Ven Cvd, Barth M, Czuczman M, Cairo MS. Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer (NK) Cells Significantly Mediate Rituximab Sensitive and Resistant Burkitt Lymphoma (BL) Regression and Improve Survival in Human BL Xenografted NSG Mice Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.433 |
0.395 |
|
| 2013 |
Barth MJ, Czuczman MS. Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia. Future Oncology (London, England). 9: 1829-39. PMID 24295413 DOI: 10.2217/Fon.13.219 |
0.494 |
|
| 2013 |
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6624-32. PMID 24130072 DOI: 10.1158/1078-0432.Ccr-13-1120 |
0.439 |
|
| 2013 |
Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. British Journal of Haematology. 163: 487-95. PMID 24111533 DOI: 10.1111/Bjh.12570 |
0.337 |
|
| 2013 |
Zinzani PL, Vose JM, Czuczman MS, Reeder CB, Haioun C, Polikoff J, Tilly H, Zhang L, Prandi K, Li J, Witzig TE. Long-term follow-up of lenalidomide in relapsed/ refractory mantle cell lymphoma: Subset analysis of the NHL-003 study Annals of Oncology. 24: 2892-2897. PMID 24030098 DOI: 10.1093/Annonc/Mdt366 |
0.503 |
|
| 2013 |
Gu JJ, Hernandez-Ilizaliturri FJ, Mavis C, Czuczman NM, Deeb G, Gibbs J, Skitzki JJ, Patil R, Czuczman MS. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models. Anti-Cancer Drugs. 24: 1030-8. PMID 23995855 DOI: 10.1097/Cad.0000000000000008 |
0.485 |
|
| 2013 |
Evens AM, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS, Abel GA, Millenson M, Czuczman MS, Rodriguez MA, Niland J, Zelenetz AD, Gordon LI, Friedberg JW. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer. 119: 3662-71. PMID 23921646 DOI: 10.1002/Cncr.28243 |
0.438 |
|
| 2013 |
Vose JM, Habermann TM, Czuczman MS, Zinzani PL, Reeder CB, Tuscano JM, Lossos IS, Li J, Pietronigro D, Witzig TE. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. British Journal of Haematology. 162: 639-47. PMID 23834234 DOI: 10.1111/Bjh.12449 |
0.524 |
|
| 2013 |
Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP, Czuczman NM, Mavis C, Skitzki JJ, Czuczman MS. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. British Journal of Haematology. 162: 657-69. PMID 23826755 DOI: 10.1111/Bjh.12452 |
0.51 |
|
| 2013 |
Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Henkel K, Liao Q, Edvardsen K, Jewell RC, Fecteau D, et al. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 122: 499-506. PMID 23692856 DOI: 10.1182/Blood-2012-12-472027 |
0.536 |
|
| 2013 |
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, et al. Non-Hodgkin's lymphomas, version 1.2013. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 257-72; quiz 273. PMID 23486452 DOI: 10.6004/Jnccn.2013.0037 |
0.394 |
|
| 2013 |
Abou-Nassar KE, Vanderplas A, Friedberg JW, Abel GA, Niland J, Rodriguez MA, Czuczman MS, Millenson M, Crosby A, Gordon LI, Zelenetz AD, Kaminski M, Lacasce AS. Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Leukemia & Lymphoma. 54: 2155-62. PMID 23343180 DOI: 10.3109/10428194.2013.770151 |
0.318 |
|
| 2013 |
Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, Coiffier B, Czuczman M, Giné E, Durrant S, Kneissl M, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 573-83. PMID 23295790 DOI: 10.1200/Jco.2012.42.7211 |
0.486 |
|
| 2013 |
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 314-20. PMID 23233710 DOI: 10.1200/Jco.2012.42.4101 |
0.48 |
|
| 2013 |
Lubanski PM, Czuczman MS. Lenalidomide for the treatment of B-cell lymphoma Expert Opinion On Orphan Drugs. 1: 651-659. DOI: 10.1517/21678707.2013.819287 |
0.493 |
|
| 2013 |
De Vos S, Sehn LH, Mulligan SP, Dreyling MH, Rummel MJ, Zinzani PL, Johnson DM, Evans S, Dansey RD, Godfrey WR, Czuczman MS. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL). Journal of Clinical Oncology. 31: TPS8618-TPS8618. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps8618 |
0.507 |
|
| 2013 |
Rolland D, Barth MJ, Ayello J, Ven Cvd, Czuczman MS, Elenitoba-Johnson KSJ, Lim M, Cairo MS. Global Phosphoproteomics Analysis Of Burkitt Lymphoma (BL) Demonstrates Abnormal Protein Phosphorylation In BCR, Spliceosome, mTOR and Chemokine Signaling Pathways In Rituximab Induced Resistant BL Blood. 122: 928-928. DOI: 10.1182/Blood.V122.21.928.928 |
0.366 |
|
| 2013 |
Barth MJ, Mavis C, Czuczman NM, Frys S, Klener P, Czuczman MS, Hernandez-Ilizaliturri F. MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo Blood. 122: 647-647. DOI: 10.1182/Blood.V122.21.647.647 |
0.516 |
|
| 2013 |
Frys S, Skomra A, Czuczman NM, Mavis C, Rolland DCM, Lim M, Awasthi A, Cairo MS, Czuczman MS, Hernandez-Ilizaliturri FJ, Barth MJ. The Acquirement Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K/Akt/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models Blood. 122: 5144-5144. DOI: 10.1182/Blood.V122.21.5144.5144 |
0.466 |
|
| 2013 |
Neppalli VT, Deeb G, Czuczman MS, Hernandez-Ilizaliturri FJ. Distinct CD30 Expression Patterns In Germinal Center B-Cell (GCB) and Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL) Blood. 122: 5064-5064. DOI: 10.1182/Blood.V122.21.5064.5064 |
0.468 |
|
| 2013 |
Gu J, Yanamadala V, Mavis C, Hernandez F, Czuczman MS. Altered Glucose Metabolism In Rituximab-Chemotherapy Resistant Cells Is a Potential Target For Future Therapeutic Development Blood. 122: 4413-4413. DOI: 10.1182/Blood.V122.21.4413.4413 |
0.41 |
|
| 2013 |
Belliotti S, Gu J, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ. MLN4924 An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE) Is Active In Pre-Clinical Models Of Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma Blood. 122: 4409-4409. DOI: 10.1182/Blood.V122.21.4409.4409 |
0.517 |
|
| 2013 |
Palanca-Wessels MC, Salles GA, Czuczman MS, Assouline SE, Flinn IW, Sehn LH, Patel M, Sangha R, Tilly H, Advani R, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Lu D, et al. Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Blood. 122: 4400-4400. DOI: 10.1182/Blood.V122.21.4400.4400 |
0.454 |
|
| 2013 |
Ibabao CN, Mavis C, Gu J, Czuczman MS, Hernandez F. CBL-C137, a Curaxin and Potent Suppressor Of NF-Kb Activity and Modulator Of p53 Function Is Active In Rituximab-Sensitive Or Resistant Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) Cells Blood. 122: 1836-1836. DOI: 10.1182/Blood.V122.21.1836.1836 |
0.496 |
|
| 2013 |
Gu J, Skitzki J, Hernandez F, Czuczman MS. Ixazomib, An Investigational Orally Bioavailable Proteasome Inhibitor, Increases p21 Expression Inducing Caspase-Dependent Cell Death, Cell-Cycle Arrest, and In B-Cell Lymphoma Pre-Clinical Models Blood. 122: 1828-1828. DOI: 10.1182/Blood.V122.21.1828.1828 |
0.51 |
|
| 2013 |
Singh A, Gu J, Yanamadala V, Czuczman MS, Hernandez-Ilizaliturri FJ. Metformin Lowers The Mitochondrial Potential Of Lymphoma Cells and Its Use During Front-Line Rituximab-Based Chemo-Immunotherapy Improves The Clinical Outcome Of Diffuse Large B-Cell Lymphoma Blood. 122: 1825-1825. DOI: 10.1182/Blood.V122.21.1825.1825 |
0.455 |
|
| 2013 |
Hernandez-Ilizaliturri FJ, Czuczman MS, Rodig S, Letai AG. Alterations In Mitochondrial Priming May Be a Mechanism For Acquired Resistance To Therapy In Diffuse Large B-Cell Lymphoma Blood. 122: 1764-1764. DOI: 10.1182/Blood.V122.21.1764.1764 |
0.492 |
|
| 2012 |
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, et al. Non-Hodgkin's Lymphomas, version 3.2012. Journal of the National Comprehensive Cancer Network : Jnccn. 10: 1487-98. PMID 23221787 DOI: 10.6004/Jnccn.2012.0155 |
0.451 |
|
| 2012 |
Bander NH, Czuczman MS, Younes A. Antibody-drug conjugate technology development for hematologic disorders. Clinical Advances in Hematology & Oncology : H&O. 10: 1-16. PMID 23072775 |
0.323 |
|
| 2012 |
Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Strange C, Windfeld K, Viardot A. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. British Journal of Haematology. 157: 438-45. PMID 22409295 DOI: 10.1111/J.1365-2141.2012.09086.X |
0.435 |
|
| 2012 |
Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, DiRienzo CG, Goldstein N, Gupta I, Jewell RC, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 119: 3698-704. PMID 22389254 DOI: 10.1182/Blood-2011-09-378323 |
0.518 |
|
| 2012 |
Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, Cheson BD. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 2356-62. PMID 22357442 DOI: 10.1093/Annonc/Mdr620 |
0.477 |
|
| 2012 |
LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 119: 2093-9. PMID 22234679 DOI: 10.1182/Blood-2011-07-369629 |
0.498 |
|
| 2012 |
Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH, Czuczman MS. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1039-50. PMID 22228637 DOI: 10.1158/1078-0432.Ccr-11-1429 |
0.59 |
|
| 2012 |
Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. British Journal of Haematology. 156: 490-8. PMID 22150234 DOI: 10.1111/J.1365-2141.2011.08966.X |
0.674 |
|
| 2012 |
Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 97: 758-65. PMID 22133772 DOI: 10.3324/Haematol.2011.056531 |
0.426 |
|
| 2012 |
Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, LaCasce AS. High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leukemia & Lymphoma. 53: 1113-6. PMID 22098406 DOI: 10.3109/10428194.2011.639882 |
0.422 |
|
| 2012 |
Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 118: 2944-51. PMID 22006274 DOI: 10.1002/Cncr.26588 |
0.472 |
|
| 2012 |
Dawar R, Barth MJ, Mavis C, Skitzki JJ, Czuczman MS, Klener P, Hernandez-Ilizaliturri FJ. Evaluation of MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, as a novel targeted agent with single-agent antitumor activity in mantle cell lymphoma (MCL) and Hodgkin lymphoma preclinical models. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E18539 |
0.532 |
|
| 2012 |
Jitawatanarat P, Dawar R, Chittawatanarat K, Batty N, Czuczman MS, Hernandez-Ilizaliturri FJ. Alternating non-cross-resistant multiagent chemotherapy (ANCRC) and high-dose chemotherapy followed by autologous stem cell support (HDC-ASCS) in first remission to improve outcome in patients with T-cell lymphoma. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E18538 |
0.514 |
|
| 2012 |
Barth MJ, Pendurti G, Mavis C, Czuczman N, Skitzki JJ, Hernandez-Ilizaliturri FJ, Czuczman MS. Preclinical activity of ofatumumab (OFA) in mantle cell lymphoma (MCL) in vitro, ex vivo, and in vivo models. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E18537 |
0.51 |
|
| 2012 |
Press OW, Unger JM, LeBlanc ML, Rimsza LM, Friedberg JW, Czuczman MS, Kaminski MS, Braziel RM, Spier CM, Maloney DG, Cheson BD, Miller TP, Fisher RI. A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab with CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models. Journal of Clinical Oncology. 30: 8001-8001. DOI: 10.1200/Jco.2012.30.15_Suppl.8001 |
0.464 |
|
| 2012 |
Runckel K, Mavis C, Skitzki J, Czuczman MS, Hernandez-Ilizaliturri FJ. The SMAC Mimetic Lcl-161 Demonstrates Anti-Tumor Activity As a Single Agent and Decreases the Apoptotic Threshold of Chemotherapy Agents in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Pre-Clinical Models Blood. 120: 61-61. DOI: 10.1182/Blood.V120.21.61.61 |
0.535 |
|
| 2012 |
Palanca-Wessels MC, Flinn IW, Sehn LH, Patel M, Sangha R, Czuczman MS, Salles GA, Morschhauser F, Advani R, Press OW, Ho W, Kahn R, Lu D, Su Z, Chu Y, et al. A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Blood. 120: 56-56. DOI: 10.1182/Blood.V120.21.56.56 |
0.465 |
|
| 2012 |
Barr PM, Hernandez-Ilizaliturri FJ, Murante T, Hilchey SP, Peterson DR, Kelly JL, Johnson DM, Lannutti BJ, Czuczman MS, Friedberg JW, Bernstein SH. Comprehensive in Vitro and in Vivo Analysis of Phosphatidylinositol-3-Kinase Delta (PI3Kδ) Inhibition Using GS-1101 (CAL-101) in Combination with Mammalian Target of Rapamycin (mTOR) Inhibition Using Temsirolimus or Everolimus in Mantle Cell Lymphoma (MCL) Blood. 120: 3719-3719. DOI: 10.1182/Blood.V120.21.3719.3719 |
0.443 |
|
| 2012 |
Herko A, Mavis C, Czuczman MS, Hernandez F. AMG 319, a Novel Inhibitor of Phosphoinositide-3 Kinase Delta (PI3Kd), Demonstrates Activity in Lymphoma Pre-Clinical Models Blood. 120: 3718-3718. DOI: 10.1182/Blood.V120.21.3718.3718 |
0.533 |
|
| 2012 |
Barth MJ, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS. MLN4924, an Investigational Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Inhibits NF-κB Activity and Induces G1 Cell Cycle Arrest and Apoptosis in Pre-Clinical Models of Hodgkin Lymphoma (HL) Blood. 120: 3717-3717. DOI: 10.1182/Blood.V120.21.3717.3717 |
0.469 |
|
| 2012 |
Czuczman MS, Lamonica D, Gaylor SK, Bush L, Nadolny P, Colborn D. Open-Label Bendamustine Combined with Rituximab for Treatment of Relapsed/Refractory Mantle-Cell Lymphoma: Efficacy and Safety Findings Blood. 120: 3662-3662. DOI: 10.1182/Blood.V120.21.3662.3662 |
0.514 |
|
| 2012 |
Czuczman NM, Barth MJ, Dwar R, Mavis C, Klener P, Czuczman MS, Hernandez-Ilizaliturri FJ. Evaluation of the Anti-Tumor Activity of MLN4924, A Novel NEDD8 Activating Enzyme Inhibitor, in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma. Blood. 120: 2761-2761. DOI: 10.1182/Blood.V120.21.2761.2761 |
0.522 |
|
| 2012 |
Klener P, Klanova M, Soukup T, Molinsky J, Zivny J, Trneny M, Hernandez-Ilizaliturri FJ, Czuczman MS, Necas E. Mouse Models of Human Mantle Cell Lymphoma for the Study of Disease Biology and for Pre-Clinical Assessment of Experimental Treatment Approaches. Blood. 120: 2759-2759. DOI: 10.1182/Blood.V120.21.2759.2759 |
0.483 |
|
| 2012 |
Barth MJ, Pendurti G, Tsai P, Mavis C, Klener P, Czuczman MS, Hernandez-Ilizaliturri F. Ofatumumab (OFA) Is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity in Vitro and in Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models. Blood. 120: 2757-2757. DOI: 10.1182/Blood.V120.21.2757.2757 |
0.677 |
|
| 2012 |
Miller J, Barth MJ, Mavis C, Tsai P, Klener P, Hernandez-Ilizaliturri F, Czuczman MS. Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab–resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In vitro and in Vivo models. Blood. 120: 2756-2756. DOI: 10.1182/Blood.V120.21.2756.2756 |
0.707 |
|
| 2012 |
Zinzani PL, Vose JM, Czuczman MS, Reeder C, Haioun C, Polikoff J, Tilly H, Pietronigro D, Ervin-Haynes A, Li J, Witzig TE. Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study. Blood. 120: 2738-2738. DOI: 10.1182/Blood.V120.21.2738.2738 |
0.442 |
|
| 2012 |
Ban-Hoefen M, Vanderplas A, Kelly JL, Crosby-Thompson A, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson M, Nademanee A, Rodriguez MA, Zelenetz AD, Niland J, LaCasce A, Friedberg JW. Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database. Blood. 120: 2669-2669. DOI: 10.1182/Blood.V120.21.2669.2669 |
0.343 |
|
| 2012 |
Zhou Z, Rademaker AW, Gordon LI, LaCasce AS, Vanderplas A, Crosby-Thompson A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Friedberg JW, et al. An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database. Blood. 120: 2656-2656. DOI: 10.1182/Blood.V120.21.2656.2656 |
0.388 |
|
| 2012 |
Gu J, Hernandez-Ilizaliturri F, Kaufman GP, Mavis C, Czuczman MS. Bortezomib (BTZ) Inhibits p21-Dependent Senescence and Triggers Mitotic Catastrophe in Rituximab-Chemotherapy Resistant Cell Lines (RRCL) Blood. 120: 1655-1655. DOI: 10.1182/Blood.V120.21.1655.1655 |
0.523 |
|
| 2012 |
Frys S, Barth MJ, Mavis C, Gu J, Gibbs J, Czuczman MS, Hernandez-Ilizaliturri F. Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Is Active in B-Cell Lymphoma and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors Blood. 120: 1649-1649. DOI: 10.1182/Blood.V120.21.1649.1649 |
0.514 |
|
| 2012 |
Czuczman MS, Hess G, Gadeberg O, Pedersen LM, Hansen P, Belada D, Gregory SA, Pohlman B, Mayer J, Pytlik R, Trumper L, Viardot A, Gupta IV, Lin TS, Winter P, et al. Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results Blood. 120: 1632-1632. DOI: 10.1182/Blood.V120.21.1632.1632 |
0.396 |
|
| 2012 |
Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson M, Nademanee A, Niland J, Rodriguez MA, Zelenetz AD, LaCasce AS. Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN Blood. 120: 1610-1610. DOI: 10.1182/Blood.V120.21.1610.1610 |
0.448 |
|
| 2012 |
Thudium KE, Wollenberg L, Mavis C, Czuczman MS, Fetterly GJ, Hernandez-Ilizaliturri F. Abstract 3709: Synergistic effects of obatoclax (GX15-070) and bortezomib (BTZ) in non-Hodgkin's lymphoma Cancer Research. 72: 3709-3709. DOI: 10.1158/1538-7445.Am2012-3709 |
0.508 |
|
| 2011 |
Chanan-Khan AA, Chitta K, Ersing N, Paulus A, Masood A, Sher T, Swaika A, Wallace PK, Mashtare TL, Wilding G, Lee K, Czuczman MS, Borrello I, Bangia N. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. British Journal of Haematology. 155: 457-67. PMID 22010965 DOI: 10.1111/J.1365-2141.2011.08882.X |
0.401 |
|
| 2011 |
Derby L, Czuczman MS. Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders. Future Oncology (London, England). 7: 963-79. PMID 21823892 DOI: 10.2217/Fon.11.79 |
0.44 |
|
| 2011 |
Czuczman MS, Vose JM, Witzig TE, Zinzani PL, Buckstein R, Polikoff J, Li J, Pietronigro D, Ervin-Haynes A, Reeder CB. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. British Journal of Haematology. 154: 477-81. PMID 21707581 DOI: 10.1111/J.1365-2141.2011.08781.X |
0.475 |
|
| 2011 |
Sher T, Ailawadhi S, Miller KC, Manfredi D, Wood M, Tan W, Wilding G, Czuczman MS, Hernandez-Ilizaliturri FJ, Hong F, Sood R, Soniwala S, Lawrence W, Jamshed S, Masood A, et al. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. British Journal of Haematology. 154: 104-10. PMID 21554260 DOI: 10.1111/J.1365-2141.2011.08703.X |
0.481 |
|
| 2011 |
Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, et al. Non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 484-560. PMID 21550968 DOI: 10.6004/Jnccn.2011.0046 |
0.362 |
|
| 2011 |
Chanan-Khan A, Miller KC, Lawrence D, Padmanabhan S, Miller A, Hernandez-Illatazurri F, Czuczman MS, Wallace PK, Zeldis JB, Lee K. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 117: 2127-35. PMID 21523725 DOI: 10.1002/Cncr.25748 |
0.448 |
|
| 2011 |
Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Goy A, Witzig TE, Czuczman MS. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 117: 5058-66. PMID 21495023 DOI: 10.1002/Cncr.26135 |
0.484 |
|
| 2011 |
Brem EA, Thudium K, Khubchandani S, Tsai PC, Olejniczak SH, Bhat S, Riaz W, Gu J, Iqbal A, Campagna R, Knight J, Mavis C, Hoskin P, Deeb G, Gibbs JF, ... ... Czuczman MS, et al. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. British Journal of Haematology. 153: 599-611. PMID 21492126 DOI: 10.1111/J.1365-2141.2011.08669.X |
0.654 |
|
| 2011 |
Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma Annals of Oncology. 22: 1622-1627. PMID 21228334 DOI: 10.1093/Annonc/Mdq626 |
0.54 |
|
| 2011 |
Oliansky DM, Czuczman M, Fisher RI, Irwin FD, Lazarus HM, Omel J, Vose J, Wolff SN, Jones RB, McCarthy PL, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 17: 20-47.e30. PMID 20656046 DOI: 10.1016/J.Bbmt.2010.07.008 |
0.43 |
|
| 2011 |
Bhat SA, Czuczman MS. Humanized anti-CD20 monoclonal antibody oncolytic Drugs of the Future. 36: 519-526. DOI: 10.1358/dof.2011.036.07.1638800 |
0.398 |
|
| 2011 |
Press OW, Unger JM, Rimsza LM, Friedberg J, LeBlanc M, Czuczman MS, Kaminski MS, Braziel RM, Maloney DG, Cheson BD, Miller TP, Fisher RI. A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma Blood. 118: 98-98. DOI: 10.1182/Blood.V118.21.98.98 |
0.476 |
|
| 2011 |
Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Liao Q, Edvardsen K, Lisby S, Moskowitz CH. A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT) Blood. 118: 957-957. DOI: 10.1182/Blood.V118.21.957.957 |
0.505 |
|
| 2011 |
Fowler NH, Kahanic SP, Forero A, Munteanu MC, Davis GL, Brown P, Neste EVD, Offner FC, Bron D, Czuczman MS. Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin9s Lymphoma Blood. 118: 778-778. DOI: 10.1182/Blood.V118.21.778.778 |
0.541 |
|
| 2011 |
Barth MJ, Pendurty G, Mavis C, Czuczman NM, Gibbs J, Deeb G, Czuczman MS, Hernandez-Ilizaliturri FJ. Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) in Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived From Patient Tumor Samples Blood. 118: 4972-4972. DOI: 10.1182/Blood.V118.21.4972.4972 |
0.521 |
|
| 2011 |
Gu J, Czuczman NM, Kaufman GP, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS. The Novel Proteasome Inhibitor Carfilzomib (CFZ) Potentiates the Anti-Tumor Activity of Chemotherapeutic Agents in Rituximab-Chemotherapy Resistant Lymphoma Through Inducing G2/M Cell Cycle Arrest and Cell Death Blood. 118: 4970-4970. DOI: 10.1182/Blood.V118.21.4970.4970 |
0.525 |
|
| 2011 |
Gu J, Hernandez-Ilizaliturri FJ, Mavis C, Czuczman NM, Thudium KE, Deeb G, Gibbs J, Czuczman MS. Apoptotic and Non-Apoptotic Cellular Pathways Executed by Bortezomib (BTZ) in Rituximab-Resistant Lymphomas Blood. 118: 4967-4967. DOI: 10.1182/Blood.V118.21.4967.4967 |
0.518 |
|
| 2011 |
Evens AM, Vanderplas A, LaCasce A, Crosby A, Nademanee A, Kaminski MS, Abel GA, Millenson M, Czuczman MS, Rodriguez MA, Niland J, Zelenetz AD, Gordon LI, Friedberg J. Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project, Blood. 118: 4112-4112. DOI: 10.1182/Blood.V118.21.4112.4112 |
0.419 |
|
| 2010 |
Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. The Lancet. Oncology. 11: 1149-59. PMID 21094089 DOI: 10.1016/S1470-2045(10)70261-8 |
0.401 |
|
| 2010 |
Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM, Klein J, Halpern W, Miceli R, Kumm E, Fox NL, Czuczman MS. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma British Journal of Cancer. 103: 1783-1787. PMID 21081929 DOI: 10.1038/Sj.Bjc.6605987 |
0.521 |
|
| 2010 |
Olejniczak SH, Blickwedehl J, Belicha-Villanueva A, Bangia N, Riaz W, Mavis C, Clements JL, Gibbs J, Hernandez-Ilizaliturri FJ, Czuczman MS. Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Blood. 116: 5605-14. PMID 20930068 DOI: 10.1182/Blood-2009-12-259754 |
0.465 |
|
| 2010 |
Czuczman M, Straus D, Gribben J, Bredenfeld H, Friedberg J, Bollard C. Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas. Leukemia & Lymphoma. 51: 41-49. PMID 20658953 DOI: 10.3109/10428194.2010.500083 |
0.409 |
|
| 2010 |
Czuczman MS, Leonard JP, Williams ME. Clinical roundtable monograph: Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion. Clinical Advances in Hematology & Oncology : H&O. 8: 1-14; quiz 2p follow. PMID 20539272 |
0.369 |
|
| 2010 |
Elefante A, Czuczman MS. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 67: 713-23. PMID 20410545 DOI: 10.2146/Ajhp090328 |
0.394 |
|
| 2010 |
Czuczman MS, Rummel MJ. Clinical Roundtable Monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana. Clinical Advances in Hematology & Oncology : H&O. 8: A1-11. PMID 20391648 |
0.431 |
|
| 2010 |
Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leukemia & Lymphoma. 51: 983-94. PMID 20367564 DOI: 10.3109/10428191003717746 |
0.472 |
|
| 2010 |
Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, Sierra J, Smith MR, Verhoef G, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2085-93. PMID 20308665 DOI: 10.1200/Jco.2009.25.1900 |
0.54 |
|
| 2010 |
Reddy N, Czuczman MS. Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: Preclinical mechanistic studies Annals of Oncology. 21: 1756-1764. PMID 20133382 DOI: 10.1093/Annonc/Mdq009 |
0.391 |
|
| 2010 |
Bhat S, Czuczman MS. Galiximab: a review. Expert Opinion On Biological Therapy. 10: 451-8. PMID 20092425 DOI: 10.1517/14712591003596318 |
0.509 |
|
| 2010 |
Sher T, Miller KC, Lawrence D, Whitworth A, Hernandez-Ilizaliturri F, Czuczman MS, Miller A, Lawrence W, Bilgrami SA, Sood R, Wood MT, Block AW, Lee K, Chanan-Khan AA. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leukemia & Lymphoma. 51: 85-8. PMID 20055660 DOI: 10.3109/10428190903406806 |
0.417 |
|
| 2010 |
Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 116: 106-14. PMID 19890959 DOI: 10.1002/Cncr.24714 |
0.521 |
|
| 2010 |
Riaz W, Hernandez-Ilizaliturri FJ, Czuczman MS. Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. Immunologic Research. 46: 192-205. PMID 19763890 DOI: 10.1007/S12026-009-8121-X |
0.568 |
|
| 2010 |
Kaufman GP, Hernandez-Ilizaliturri FJ, Mavis C, Patil R, Czuczman MS. Evaluation of carfilzomib to disrupt the apoptotic threshold of B-cell lymphomas by targeting Bcl-2 family members and overcome rituximab (R) chemotherapy resistance. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E18514 |
0.467 |
|
| 2010 |
Belada D, Mayer J, Czuczman MS, Flinn IW, Durbin-Johnson B, Bray GL. Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL). Journal of Clinical Oncology. 28: 8104-8104. DOI: 10.1200/Jco.2010.28.15_Suppl.8104 |
0.462 |
|
| 2010 |
Lamonica DM, Hahn T, Drumsta D, Achakzai M, Czuczman MS, Hernandez-Ilizaliturri FJ. 18F-fluorodeoxglucose (FDG) positron emission tomography (PET) versus FLIPI as a predictor of therapy response in follicular lymphoma (FL) patients. Journal of Clinical Oncology. 28: 8102-8102. DOI: 10.1200/Jco.2010.28.15_Suppl.8102 |
0.301 |
|
| 2010 |
Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma. Journal of Clinical Oncology. 28: 8095-8095. DOI: 10.1200/Jco.2010.28.15_Suppl.8095 |
0.663 |
|
| 2010 |
Riaz W, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Czuczman MS. Efficacy of combination of rituximab (R), obatoclax (O), and bortezomib (B) against rituximab-sensitive (RSCL) and rituximab-resistant B-cell lymphoma cell lines (RRCL). Journal of Clinical Oncology. 28: 8094-8094. DOI: 10.1200/Jco.2010.28.15_Suppl.8094 |
0.632 |
|
| 2010 |
Patil R, Hernandez-Ilizaliturri FJ, Elefante A, Czuczman MS. Body mass index (BMI) and obesity as a predictor of clinical outcome in patients with Hodgkin's lymphoma treated with AVBD. Journal of Clinical Oncology. 28: 8063-8063. DOI: 10.1200/Jco.2010.28.15_Suppl.8063 |
0.341 |
|
| 2010 |
Czuczman M, Viardot A, Hess G, Gadeberg O, Pedersen LM, Gupta I, Lin T, Strange C, Windfeld K, Russell C. Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL). Journal of Clinical Oncology. 28: 8042-8042. DOI: 10.1200/Jco.2010.28.15_Suppl.8042 |
0.425 |
|
| 2010 |
Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Witzig TE, Goy A, Czuczman MS. Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R). Journal of Clinical Oncology. 28: 8038-8038. DOI: 10.1200/Jco.2010.28.15_Suppl.8038 |
0.44 |
|
| 2010 |
Reeder CB, Vose J, Witzig TE, Zinzani PL, Buckstein R, Polikoff J, Li J, Pietronigro D, Ervin-Haynes AL, Czuczman MS. Lenalidomide (LEN) in patients with transformed lymphoma: Results from a large international phase II study (NHL-003). Journal of Clinical Oncology. 28: 8037-8037. DOI: 10.1200/Jco.2010.28.15_Suppl.8037 |
0.408 |
|
| 2010 |
Mavis C, Frys S, Gu J, Gibbs J, Czuczman MS, Hernandez-Ilizaliturri FJ. Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines, Blood. 118: 3734-3734. DOI: 10.1182/Blood.V118.21.3734.3734 |
0.504 |
|
| 2010 |
Abou-Nassar KE, Vanderplas A, Friedberg JW, Abel G, Niland J, Rodriguez MA, Czuczman MS, Millenson M, Crosby A, Gordon LI, Zelenetz AD, LaCasce A. Patterns of Use of FDG-PET for the Initial Staging of Follicular Lymphoma (FL) and Its Impact on Initial Treatment Strategy and Outcomes In the National Comprehensive Cancer Network (NCCN) Lymphoma Database Blood. 116: 81-81. DOI: 10.1182/Blood.V116.21.81.81 |
0.314 |
|
| 2010 |
Tsai P, Dvorak P, Bangia N, Olejniczak S, Czuczman MS, Hernandez-Ilizaliturri FJ. Rituximab Resistance Is Associated with Global Downregulation of CD20 and CD54 In B-Cell Lymphoma Cells: Implication of CD20 Signaling on CD54 Blood. 116: 5077-5077. DOI: 10.1182/Blood.V116.21.5077.5077 |
0.624 |
|
| 2010 |
Gu J, Hernandez-Ilizaliturri FJ, Kaufman GP, Mavis C, Czuczman MS. Carfilzomib (CFZ): A Novel Proteasome Inhibitor That Induces Cell Cycle Arrest and Cell Death In Rituximab-Chemotherapy Resistant Lymphoma and Potentiates the Anti-Tumor Activity of Chemotherapeutic Agents Blood. 116: 4908-4908. DOI: 10.1182/Blood.V116.21.4908.4908 |
0.544 |
|
| 2010 |
Gu J, Ritesh P, Mavis C, Deeb G, Gibbs J, Hernandez-Ilizaliturri FJ, Czuczman MS. MLN2238, a Novel and Potent Proteasome Inhibitor, Induces Caspase-Dependent Cell Death, Cell-Cycle Arrest, and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Chemotherapy Sensitive or Resistant B-Cell Lymphoma Cell Lines Blood. 116: 3939-3939. DOI: 10.1182/Blood.V116.21.3939.3939 |
0.515 |
|
| 2010 |
Barth M, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs J, Deeb G, Czuczman MS. Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenografts, and Primary Tumor Cells Derived From Patients with B-Cell Non-Hodgkin Lymphoma (NHL) Blood. 116: 3917-3917. DOI: 10.1182/Blood.V116.21.3917.3917 |
0.697 |
|
| 2010 |
Love N, Gregory SA, Cheson BD, Czuczman MS, Elder M, Paley D, Ziel K. Tolerance and Response to Initial Systemic Therapy In Older Patients with Follicular Lymphoma (FL): Observations From 186 Unselected Recent Cases In the Practices of US-Based Medical Oncologists (MOs). Blood. 116: 3842-3842. DOI: 10.1182/Blood.V116.21.3842.3842 |
0.398 |
|
| 2010 |
Stein R, Chen S, Hernandez-Ilizaliturri FJ, Czuczman MS, Goldenberg DM. Milatuzumab Improves Efficacy of Current Treatments for B-Cell Malignancies. Blood. 116: 2837-2837. DOI: 10.1182/Blood.V116.21.2837.2837 |
0.467 |
|
| 2010 |
Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA. Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma In the National Comprehensive Cancer Network (NCCN) Lymphoma Database Blood. 116: 1756-1756. DOI: 10.1182/Blood.V116.21.1756.1756 |
0.411 |
|
| 2010 |
Chyla B, Smith M, Tahir S, Wilson W, O'Connor O, Czuczman M, Gerecitano J, Enschede S, Krivoshik A, McKeegan E. 611 Bcl-2 family protein expression in navitoclax-treated patients (pts) with lymphoid malignancies Ejc Supplements. 8: 192. DOI: 10.1016/S1359-6349(10)72318-1 |
0.324 |
|
| 2010 |
Czuczman MS. Unmet needs in the treatment of aggressive lymphoma Clinical Advances in Hematology and Oncology. 8: 7-8. |
0.371 |
|
| 2010 |
Czuczman MS. Novel targeted agents and monoclonal antibodies for aggressive B-cell lymphoma Clinical Advances in Hematology and Oncology. 8. |
0.313 |
|
| 2010 |
Czuczman MS, Rummel MJ. Recent advances in NHL: Highlights from the 51st ASH annual meeting and exposition, December 5-8, 2009, New Orleans, Louisiana Clinical Advances in Hematology and Oncology. 8: 1-3. |
0.421 |
|
| 2010 |
Czuczman MS, Gregory SA, van Der Jagt R. B-cell non-hodgkin lymphoma: A case-based discussion of recent advances in patient management Clinical Advances in Hematology and Oncology. 8: 1-15. |
0.409 |
|
| 2009 |
Wilson W, O'Connor OO, Roberts AW, Czuczman M, Brown J, Xiong H, Xiong H, Chiu Y, Krivoshik A, Enschede S, Humerickhouse R. ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8574. PMID 27962273 DOI: 10.1200/Jco.2009.27.15_Suppl.8574 |
0.428 |
|
| 2009 |
Reeder CB, Witzig TE, Zinzani PL, Vose JM, Buckstein R, Haioun C, Bouabdallah R, Polikoff J, Pietronigro D, Czuczman MS. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: Results from an international study (NHL-003). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8569. PMID 27961025 DOI: 10.1200/jco.2009.27.15_suppl.8569 |
0.37 |
|
| 2009 |
Czuczman MS, Vose J, Zinzani P, Reeder C, Buckstein R, Haioun C, Bouabdallah R, Polikoff J, Ervin-Haynes A, Witzig T. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e19504. PMID 27960873 DOI: 10.1200/Jco.2009.27.15_Suppl.E19504 |
0.541 |
|
| 2009 |
Bhat SA, Czuczman MS. Novel antibodies in the treatment of non-Hodgkin's lymphoma Netherlands Journal of Medicine. 67: 311-321. PMID 19767657 |
0.394 |
|
| 2009 |
Radich JP, Zelenetz AD, Chan WC, Croce CM, Czuczman MS, Erba HP, Horning SJ, Houldsworth J, Smith BD, Snyder DS, Sundar HM, Wetzler M, Winter JN. NCCN task force report: molecular markers in leukemias and lymphomas. Journal of the National Comprehensive Cancer Network : Jnccn. 7: S1-34, quiz S35-6. PMID 19635230 DOI: 10.6004/Jnccn.2009.0077 |
0.427 |
|
| 2009 |
Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies. Oncology (Williston Park, N.Y.). 23: 610-5. PMID 19626827 |
0.405 |
|
| 2009 |
Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches. Oncology (Williston Park, N.Y.). 23: 546-53. PMID 19544696 |
0.453 |
|
| 2009 |
Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Current Opinion in Investigational Drugs (London, England : 2000). 10: 579-87. PMID 19513947 |
0.435 |
|
| 2009 |
Chanan-Khan A, Miller KC, Musial L, Padmanabhan S, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein ZP, Barcos M, Patel M, Iancu D, Lee K, Czuczman MS. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leukemia & Lymphoma. 50: 1096-101. PMID 19479618 DOI: 10.1080/10428190902912460 |
0.486 |
|
| 2009 |
Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 113: 6069-76. PMID 19380866 DOI: 10.1182/Blood-2009-01-199679 |
0.484 |
|
| 2009 |
Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HJ, Chang CH. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 113: 1062-70. PMID 18941114 DOI: 10.1182/Blood-2008-07-168146 |
0.452 |
|
| 2009 |
Hernandez-Ilizaliturri FJ, Czuczman MS. A Review of Nelarabine in the Treatment of T-cell Lymphoblastic Leukemia/Lymphoma Clinical Medicine and Therapeutics. 2009: 505-511. DOI: 10.4137/Cmt.S1954 |
0.349 |
|
| 2009 |
Khubchandani S, Czuczman MS. Targeted therapies in B-cell non-Hodgkin lymphomas Therapy. 6: 371-380. DOI: 10.2217/Thy.09.19 |
0.484 |
|
| 2009 |
Ritesh P, Pahuja S, Chavez J, Braddy W, Skipper M, Bernstein ZP, Chanan-Khan A, Ramanarayanan J, Czuczman MS, Hernandez-Ilizaliturri FJ. Correlation of surface expression of CD11b or CD32 in polymorphonuclear cells (PMNs) and CD69 in natural killer cells (NK) with progression-free survival (PFS) following chemoimmunotherapy with rituximab and liposomal doxorubicin (LD) in patients (pts) with relapsed or refractory B-cell lymphoma Journal of Clinical Oncology. 27: 8583-8583. DOI: 10.1200/Jco.2009.27.15_Suppl.8583 |
0.509 |
|
| 2009 |
Maraj I, Hernandez-Ilizaliturri FJ, Chisti M, Czuczman MS. Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib Journal of Clinical Oncology. 27: 8576-8576. DOI: 10.1200/Jco.2009.27.15_Suppl.8576 |
0.514 |
|
| 2009 |
Hernandez-Ilizaliturri FJ, Khubchandani S, Olejniczak SH, Hoskin P, Czuczman MS. Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL) Journal of Clinical Oncology. 27: 8543-8543. DOI: 10.1200/Jco.2009.27.15_Suppl.8543 |
0.449 |
|
| 2009 |
Hagenbeek A, Fayad L, Delwail V, Rossi JF, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, Gupta I, Arning M, Begtrup K, Schultz M, ... ... Czuczman MS, et al. Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma. Blood. 114: 935-935. DOI: 10.1182/Blood.V114.22.935.935 |
0.551 |
|
| 2009 |
Chavez J, Walsh M, Hernandez-Ilizaliturri FJ, Elefante A, Czuczman MS. Classification of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) According to the Han's Criteria Defines Two Groups of Patients with Different Clinical Outcomes Following Systemic Rituximab-Multi Agent Anthracycline-Based Therapy. Blood. 114: 623-623. DOI: 10.1182/Blood.V114.22.623.623 |
0.546 |
|
| 2009 |
Sher T, Miller KC, Ailawadhi S, Manfredi D, Wood M, Tan W, Wilding G, Liu H, Czuczman MS, Hernandez F, Hong F, Sood R, Soniwalla S, Lawrence W, Kouides PA, et al. Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study. Blood. 114: 618-618. DOI: 10.1182/Blood.V114.22.618.618 |
0.48 |
|
| 2009 |
Dang NH, Smith MR, Offner F, Verhoef G, Johnson P, Rohatiner AZS, Kaufman JL, Gine E, Coiffier B, Czuczman MS, Foran J, Durrant S, Hua S, Vandendries ER, Fayad L. Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma. Blood. 114: 584-584. DOI: 10.1182/Blood.V114.22.584.584 |
0.536 |
|
| 2009 |
LaCasce A, Vandergrift JL, Rodriguez MA, Crosby AL, Lepisto EM, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Abel GA, Zelenetz AD, Friedberg JW. R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project. Blood. 114: 403-403. DOI: 10.1182/Blood.V114.22.403.403 |
0.433 |
|
| 2009 |
Ashraf U, Czuczman MS, Marvis C, Gibbs J, Hernandez-Ilizaliturri FJ. Entinostat (SNDX-275), a Novel DAC Inhibitor, Is Highly Effective in Rituximab- [Chemotherapy]-Sensitive or Rituximab-[Chemotherapy]-Resistant Lymphomas and Has Synergistic Anti-Tumor Activity When Combined with Bortezomib. Blood. 114: 3727-3727. DOI: 10.1182/Blood.V114.22.3727.3727 |
0.534 |
|
| 2009 |
Hernandez-Ilizaliturri F, Tsio P, Campagna R, Marvis C, Riaz W, Gruber E, Gibbs J, Czuczman MS. Obatoclax and Bortezomib Therapy Results in Disruption of the p53-Mediated Apoptosis/Autophagy Pathway and Is Associated with Potent Synergistic Anti-Tumor Activity against Rituximab-Chemotherapy-Sensitive and -Resistant B-Cell Lymphoma. Blood. 114: 288-288. DOI: 10.1182/Blood.V114.22.288.288 |
0.549 |
|
| 2009 |
Hernandez-Ilizaliturri FJ, Marvis C, Maraj I, Chisti MM, Gibbs J, Czuczman MS. The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies. Blood. 114: 2715-2715. DOI: 10.1182/Blood.V114.22.2715.2715 |
0.552 |
|
| 2009 |
Vose JM, Habermann T, Czuczman MS, Zinzani PL, Reeder CB, Tuscano J, Lossos IS, Pietronigro D, Ervin-Haynes A, Witzig T. Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma Who Had Received Prior Stem Cell Transplant. Blood. 114: 2699-2699. DOI: 10.1182/Blood.V114.22.2699.2699 |
0.523 |
|
| 2009 |
Wilson WH, O'Connor OA, Czuczman MS, LaCasce A, Gerecitano J, Leonard JP, Tulpule A, Xiong H, Chiu Y, Busman T, Enschede S, Krivoshik A, Humerickhouse R. Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies. Blood. 114: 1711-1711. DOI: 10.1182/Blood.V114.22.1711.1711 |
0.412 |
|
| 2009 |
Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff J, Guo P, Pietronigro D, Ervin-Haynes A, Czuczman MS. Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003). Blood. 114: 1676-1676. DOI: 10.1182/Blood.V114.22.1676.1676 |
0.55 |
|
| 2009 |
Abel GA, Vanderplas A, Friedberg JW, Niland J, Rodriguez MA, Czuczman MS, Millenson M, Crosby AL, Gordon LI, Blayney DW, Zelenetz AD, LaCasce AS. Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database. Blood. 114: 1387-1387. DOI: 10.1182/Blood.V114.22.1387.1387 |
0.419 |
|
| 2008 |
Czuczman MS, Reeder CB, Polikoff J, Chowhan NM, Esseessee I, Greenberg R, Ervin-Haynes A, Pietronigro D, Zeldis JB, Witzig TE. International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 8509. PMID 27950988 DOI: 10.1200/Jco.2008.26.15_Suppl.8509 |
0.434 |
|
| 2008 |
Wilson WH, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Dunleavy K, Krivoshik AP, Xiong H, Chiu Y, O'Connor OA. A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 8511. PMID 27950969 DOI: 10.1200/Jco.2008.26.15_Suppl.8511 |
0.403 |
|
| 2008 |
Vinjamaram S, Czuczman MS, Hernandez-Ilizaliturri FJ. The use of galiximab in non-Hodgkin lymphoma. Clinical Lymphoma & Myeloma. 8: 277-82. PMID 18854281 DOI: 10.3816/Clm.2008.N.038 |
0.556 |
|
| 2008 |
Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6154-60. PMID 18829494 DOI: 10.1158/1078-0432.Ccr-08-0404 |
0.424 |
|
| 2008 |
O'Connor OA, Czuczman MS. Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation. Leukemia & Lymphoma. 49: 59-66. PMID 18821434 DOI: 10.1080/10428190802365033 |
0.472 |
|
| 2008 |
Czuczman MS. Sixth International Workshop on non-Hodgkin Lymphoma: 16-17 November 2007, Boston, USA. Leukemia & Lymphoma. 49: 4-6. PMID 18821427 DOI: 10.1080/10428190802311466 |
0.355 |
|
| 2008 |
LaCasce AS, Kho ME, Friedberg JW, Niland JC, Abel GA, Rodriguez MA, Czuczman MS, Millenson MM, Zelenetz AD, Weeks JC. Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5107-12. PMID 18768434 DOI: 10.1200/Jco.2008.16.4061 |
0.386 |
|
| 2008 |
Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1561-70. PMID 18316581 DOI: 10.1158/1078-0432.Ccr-07-1254 |
0.39 |
|
| 2008 |
Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1550-60. PMID 18316580 DOI: 10.1158/1078-0432.Ccr-07-1255 |
0.512 |
|
| 2008 |
Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL, Hahn T. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplantation. 41: 613-9. PMID 18071290 DOI: 10.1038/Sj.Bmt.1705951 |
0.45 |
|
| 2008 |
Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. British Journal of Haematology. 140: 36-45. PMID 17995965 DOI: 10.1111/J.1365-2141.2007.06841.X |
0.463 |
|
| 2008 |
Habermann TM, Witzig TE, Lossos IS, Vose JM, Wiernik PH, Weiss L, Ervin-Haynes A, Pietronigro D, Zeldis JB, Czuczman M. Safety of lenalidomide monotherapy in patients with relapsed or refractory aggressive non-Hodgkin’s lymphom Journal of Clinical Oncology. 26: 8603-8603. DOI: 10.1200/Jco.2008.26.15_Suppl.8603 |
0.457 |
|
| 2008 |
Hernandez-Ilizaliturri FJ, Khubchandani S, Olejniczak SH, Hosking P, Gruber E, Czuczman M. The BH3-Mimetic Obatoclax (GX15-070) Posses a Dual-Mechanism of Action and Induces Both Apoptosis and Autophagy-Dependent Cell Death of B Cell Non-Hodgkin’s Lymphoma (B-NHL) Cells Blood. 112: 605-605. DOI: 10.1182/Blood.V112.11.605.605 |
0.494 |
|
| 2008 |
Khubchandani S, Mashtare T, Chisti MM, Wilding G, Olejniczak S, Czuczman MS, Hernandez-Ilizaliturri FJ. CD20 Antigen Density at Time of Presentation Is An Independent Predictor of Outcome in B-Cell Lymphoproliferative Disorders Blood. 112: 5312-5312. DOI: 10.1182/Blood.V112.11.5312.5312 |
0.499 |
|
| 2008 |
Ramanarayanan J, Pahuja S, Czuczman MS, Hernandez-Ilizaliturri FJ. Tumor Necrosis Factor Alpha (TNF-a) Blockade and Risk of Lymphoma: Systematic Review and Analysis of Literature Blood. 112: 5278-5278. DOI: 10.1182/Blood.V112.11.5278.5278 |
0.33 |
|
| 2008 |
Maraj I, Hernandez-Ilizaliturri FJ, Chisti MM, Czuczman MS. The DAC Inhibitor LBH589 Is Highly Effective in Both “Therapy”-Sensitive and -Resistant Lymphomas and Enhances the Anti-Tumor Activity of Chemotherapy Agents, Monoclonal Antibodies, and Bortezomib Blood. 112: 4984-4984. DOI: 10.1182/Blood.V112.11.4984.4984 |
0.552 |
|
| 2008 |
Sher T, Patel M, Whitworth A, Miller K, Musial L, Lawrence D, Padmanabhan S, Ailawadhi S, Wilding G, DePaolo D, Bangia N, Czuczman MS, Wallace PK, Lee KP, Khan AC. Lenalidomide Associated Tumor Flare Reaction Correlates with Clinical Response in Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia Blood. 112: 4163-4163. DOI: 10.1182/Blood.V112.11.4163.4163 |
0.448 |
|
| 2008 |
Fayad L, Patel H, Verhoef G, Smith MR, Johnson PWM, Czuczman MS, Coiffier B, Hess G, Gine E, Advani A, Offner F, Vandendries ER, Shapiro M, Dang NH. Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study Blood. 112: 266-266. DOI: 10.1182/Blood.V112.11.266.266 |
0.538 |
|
| 2008 |
Zinzani PL, Witzig TE, Vose JM, Reeder CB, Buckstein R, Haioun C, Bouabdallah R, Polikoff J, Guo P, Ervin-Hayes A, Pietronigro D, Zeldis JB, Czuczman MS. Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: Results of An International Study (NHL-003) Blood. 112: 262-262. DOI: 10.1182/Blood.V112.11.262.262 |
0.516 |
|
| 2008 |
Tsai P, Bangia N, Olejniczak S, Hernandez-Ilizaliturri FJ, Czuczman M. The Acquirement of Rituximab Resistance Is Associated with a Global Downregulation of CD54 in B-Cell Lymphoma Cells: The Potential Role of Adhesion Molecules in Rituximab Anti-Tumor Activity Blood. 112: 2607-2607. DOI: 10.1182/Blood.V112.11.2607.2607 |
0.651 |
|
| 2008 |
Wilson WH, O’Connor O, Czuczman MS, LaCasce A, Gerecitano J, Leonard JP, Tulpule A, Xiong H, Chiu Y, Busman T, Knight RA, Enschede S, Krivoshik A, Humerickhouse R. Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies. Blood. 112: 2108-2108. DOI: 10.1182/Blood.V112.11.2108.2108 |
0.427 |
|
| 2008 |
Reeder CB, Witzig TE, Vose JM, Zinzani PL, Buckstein R, Haioun C, Bouabdallah R, Polikoff J, Guo P, Ervin-Haynes A, Pietronigro D, Zeldis JB, Czuczman MS. The Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Mantle Cell Lymphoma Previously Treated with Bortezomib: Pooled Data from Two Phase II Studies (NHL-002 and NHL-003). Blood. 112: 1560-1560. DOI: 10.1182/Blood.V112.11.1560.1560 |
0.516 |
|
| 2008 |
Ashraf U, Mahajan R, Hahn T, Smiley SL, McCarthy PL, Bernstein ZP, Chanan-Khan AA, Battiwala M, Czuczman MS, Hernandez-Ilizaliturri FJ. The Effects of Rituximab Added to Front-Line or Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT). Blood. 112: 1138-1138. DOI: 10.1182/Blood.V112.11.1138.1138 |
0.511 |
|
| 2008 |
Friedberg JW, Younes A, Fisher DC, Gordon LI, Moore JO, Czuczman MS, Miller TP, Stiff PJ, Cheson BD, Forero-Torres A, McKinney B, Leonard JP. Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial. Blood. 112: 1004-1004. DOI: 10.1182/Blood.V112.11.1004.1004 |
0.51 |
|
| 2008 |
Czuczman MS, Leonard JP, Johnson JL, Jung SH, Hsi E, Byrd JC, Cheson BD. FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R]. Blood. 112: 1003-1003. DOI: 10.1182/Blood.V112.11.1003.1003 |
0.483 |
|
| 2007 |
Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, Thurberg BL, Kennedy W, Czuczman MS. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leukemia & Lymphoma. 48: 2424-36. PMID 18067019 DOI: 10.1080/10428190701647879 |
0.445 |
|
| 2007 |
Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4556-64. PMID 17671142 DOI: 10.1158/1078-0432.Ccr-07-0680 |
0.38 |
|
| 2007 |
Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 18: 1216-23. PMID 17470451 DOI: 10.1093/Annonc/Mdm114 |
0.449 |
|
| 2007 |
Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Kelly M, Hsi ED, Cook JR, Canellos G, Cheson BD. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leukemia & Lymphoma. 48: 97-103. PMID 17325852 DOI: 10.1080/10428190600961058 |
0.43 |
|
| 2007 |
Cai S, Cannizzo F, Bullard Dunn KM, Gibbs JF, Czuczman M, Rajput A. The role of surgical intervention in non-Hodgkin's lymphoma of the colon and rectum American Journal of Surgery. 193: 409-412. PMID 17320545 DOI: 10.1016/J.Amjsurg.2006.12.007 |
0.359 |
|
| 2007 |
Reddy NM, Hernandez-Ilizalituri F, Knight J, Czuczman MS. Antitumor effects of lenalidomide in combination with IDEC114 (anti CD80) in lymphoma bearing severe combined immunodeficiency (SCID) mouse model Journal of Clinical Oncology. 25: 3037-3037. DOI: 10.1200/Jco.2007.25.18_Suppl.3037 |
0.47 |
|
| 2007 |
Ferrajoli A, Keating MJ, Wierda WG, O’Brien SM, Padmanabhan S, Czuczman MS, Chanan-Khan AA. Lenalidomide Is Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Carrying Unfavorable Chromosomal Abnormalities. Blood. 110: 754-754. DOI: 10.1182/Blood.V110.11.754.754 |
0.413 |
|
| 2007 |
Padmanabhan S, Elefante A, Varadarajan P, Battiwalla M, Bir A, Hahn T, Smiley S, Hernandez-Illizalitturi FJ, Miner L, Mohr A, Bernstein ZP, Chanan-Khan A, McCarthy P, Czuczman M. Outcomes of Relapsed/Refractory B-Cell Lymphoma Is Improved by Salvage Chemotherapy Consisting of Two to Three Cycles of Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Followed by Autologous Stem Cell Transplantation. Blood. 110: 5130-5130. DOI: 10.1182/Blood.V110.11.5130.5130 |
0.521 |
|
| 2007 |
Derby L, Hernandez-Ilizaliturri FJ, Segal BH, Knight J, Bushey J, Czuczman MS. Pegylated Granulocyte Colony Stimulating Factor (Peg-G-CSF) Enhances Mapatumumab-Mediated Antibody Dependent Cellular Cytotoxicity (ADCC) Against Non-Hodgkin’s Lymphoma (NHL) Cell Lines Independent of NADPH Oxidase-Derived Reactive Oxidant Intermediates (ROIs). Blood. 110: 4519-4519. DOI: 10.1182/Blood.V110.11.4519.4519 |
0.468 |
|
| 2007 |
Hernandez-Ilizaliturri FJ, Ali M, Knight J, Rustum YM, Czuczman MS. Methylseleninic Acid (MSA) Decreases DNA Synthesis, Induces Cell Death, and Sensitizes Both Rituximab Sensitive and Rituximab-Resistant Non-Hodgkin’s Lymphoma Cell Lines to the Anti-Tumor Activity of Cisplatin and Gemcitabine. Blood. 110: 4517-4517. DOI: 10.1182/Blood.V110.11.4517.4517 |
0.513 |
|
| 2007 |
Ailawadhi S, Hernandez-Ilizaliturri FJ, Miner L, Bernstein ZP, Chanan-Khan A, Miller KC, Mohr A, Starostik P, Czuczman MS, Padmanabhan S. Differences in BCL-2 Protein and t(14;18) in Patients with Primary Rituximab/Chemotherapy Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 110: 4433-4433. DOI: 10.1182/Blood.V110.11.4433.4433 |
0.487 |
|
| 2007 |
Chanan-Khan AA, Miller KC, DePaolo D, Padmanabhan S, Whitworth A, Ailawadhi S, Lee K, Czuczman MS. Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT) for the Treatment of Previously Untreated Multiple Myeloma. Blood. 110: 3614-3614. DOI: 10.1182/Blood.V110.11.3614.3614 |
0.466 |
|
| 2007 |
Chanan-Khan AA, Czuczman MS, Padmanabhan S, Keating MJ, O’Brien SM, Wierda WG, Ferrajoli A. Clinical Efficacy of Lenalidomide in Fludarabine-Refractory Chronic Lymphocytic Leukemia Patients. Blood. 110: 3108-3108. DOI: 10.1182/Blood.V110.11.3108.3108 |
0.471 |
|
| 2007 |
Tsai P, Hernandez-Ilizaliturri FJ, Olejniczak SH, Naveen B, Czuczman MS. Modulation of CD20 Expression in Rituximab-Sensitive (RSCL) and Rituximab Resistant Cell Lines (RRCL) Using IL-4 and Bryostatin-1. Blood. 110: 2619-2619. DOI: 10.1182/Blood.V110.11.2619.2619 |
0.594 |
|
| 2007 |
Witzig TE, Reeder CB, Polikoff J, Chowhan NM, Esseessee I, Greenberg R, Patel H, Vafai D, Wiernik PH, Ervin-Haynes A, Pietronigro D, Zeldis JB, Czuczman M. Initial Results from an International Study in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma To Confirm the Activity, Safety and Criteria for Predicting Response to Lenalidomide Monotherapy. Blood. 110: 2572-2572. DOI: 10.1182/Blood.V110.11.2572.2572 |
0.495 |
|
| 2007 |
Ashraf U, Elefante AN, Cruz R, Wallace PK, Czuczman MS, Hernandez-llizaliturri FJ. Emergence of Rituximab-Fludarabine Resistance Is Associated with Changes in CD20 Antigen Expression and Improved Response to Almetuzumab Therapy in Patients with Chronic Lymphocytic Leukemia (CLL). Blood. 110: 2054-2054. DOI: 10.1182/Blood.V110.11.2054.2054 |
0.473 |
|
| 2007 |
Gruber EA, Czuczman MS, Olejniczak SH, Knight J, Hernandez-Ilizaliturri FJ. GX15-070 and Bortezomib Induce Up-Regulation of BH3 Single Domain Pro-Apoptotic Proteins Puma and Noxa and Is Associated with Synergistic Anti-Tumor Activity in Rituximab-Sensitive, Rituximab-Resistant Cell Lines (RSCL and RRCL), and Primary Lymphoma Patient Specimens. Blood. 110: 1389-1389. DOI: 10.1182/Blood.V110.11.1389.1389 |
0.518 |
|
| 2007 |
Czuczman MS, Skipper M, Mohr A, Bernstein ZP, Hernandez-Ilizaliturri FJ, Chanan-Khan AA. Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Clinical Efficacy without Cardiac Toxicity. Blood. 110: 1369-1369. DOI: 10.1182/Blood.V110.11.1369.1369 |
0.466 |
|
| 2007 |
Kahl B, Bartlett NL, Leonard JP, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, Jagt RHvd, Cheson BD. Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma. Blood. 110: 1351-1351. DOI: 10.1182/Blood.V110.11.1351.1351 |
0.538 |
|
| 2007 |
Ramanarayanan J, Krishnan GS, Czuczman MS, Hernandez-Ilizaliturri FJ. Efficacy and Safety of Rituximab in Post Transplant Lymphoproliferative Disorders (PTLD): Pooled Analysis and Review of Literature. Blood. 110: 1084-1084. DOI: 10.1182/Blood.V110.11.1084.1084 |
0.478 |
|
| 2006 |
Czuczman MS. Controversies in follicular lymphoma: "who, what, when, where, and why?" (not necessarily in that order!). Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 303-10. PMID 17124076 DOI: 10.1182/Asheducation-2006.1.303 |
0.447 |
|
| 2006 |
Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, ... ... Czuczman MS, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study Journal of Clinical Oncology. 24: 5343-5349. PMID 17088571 DOI: 10.1200/Jco.2005.05.0401 |
0.439 |
|
| 2006 |
Czuczman MS, Grillo-López AJ, Alkuzweny B, Weaver R, Larocca A, Mclaughlin P. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab Leukemia and Lymphoma. 47: 1830-1840. PMID 17064996 DOI: 10.1080/10428190600709523 |
0.456 |
|
| 2006 |
Straus DJ, Testa MA, Sarokhan BJ, Czuczman MS, Tulpule A, Turner RR, Riggs SA. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer. 107: 1909-17. PMID 16977654 DOI: 10.1002/Cncr.22221 |
0.429 |
|
| 2006 |
Olejniczak SH, Stewart CC, Donohue K, Czuczman MS. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunological Investigations. 35: 93-114. PMID 16531332 DOI: 10.1080/08820130500496878 |
0.427 |
|
| 2006 |
Miller K, Czuczman MS, Dimiceli L, Padmanabhan S, Lawrence D, Bernstein Z, Takeshita K, Spaner D, Byrne C, Crystal C, Chanan-Khan AA. Lenalidomide (L) induces high response rates with molecular remission in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL) Journal of Clinical Oncology. 24: 6517-6517. DOI: 10.1200/Jco.2006.24.18_Suppl.6517 |
0.421 |
|
| 2006 |
Hernandez-Ilizaliturri FJ, Kaur H, Bhinder A, Olejniczak S, Knight J, Czuczman MS. Impaired Ca++ mobilization in rituximab-resistant cells (RRCL) is associated with changes in the structure of CD20 antigen, down-regulation of Bax/Bak pro-apoptotic proteins and up-regulation of the endoplasmic reticulum (ER) Ca++ pump protein SERCA-3 Journal of Clinical Oncology. 24: 2516-2516. DOI: 10.1200/Jco.2006.24.18_Suppl.2516 |
0.358 |
|
| 2006 |
Reddy NM, Hernandez-Ilizaliturri FJ, Olejniczak S, Knight J, Czuczman MS. Rituximab resistance and its association with changes in the internal domain of CD20 antigen and down-regulation of pro-apoptotic protein Bax and Bak in both rituximab-resistant cell lines (RRCL) and diffuse large B-cell lymphoma (DLBCL) patient (pt) samples Journal of Clinical Oncology. 24: 17509-17509. DOI: 10.1200/Jco.2006.24.18_Suppl.17509 |
0.463 |
|
| 2006 |
Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, Vo K, Molina A. Analysis of the Incidence of Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Registration and Compassionate-Use Trials of Ibritumomab Tiuxetan Radioimmunotherapy (RIT). Blood. 108: 485-485. DOI: 10.1182/Blood.V108.11.485.485 |
0.379 |
|
| 2006 |
Olejniczak SH, Clements JL, Bangia N, Hernandez-Ilizaliturri FJ, Czuczman MS. Down-Regulation of Bax and Bak in Immuno-Chemotherapy Resistant Non-Hodgkin’s Lymphoma Cells. Blood. 108: 4758-4758. DOI: 10.1182/Blood.V108.11.4758.4758 |
0.482 |
|
| 2006 |
Cruz R, Czuczman MS, Hernandez F, Kanra A, Padmanabhan S. Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Is an Effective Salvage Regimen for Patients with Relapsed/Refractory B-Cell Lymphoma in Preparation for Autologous Stem Cell Transplantation. Blood. 108: 4730-4730. DOI: 10.1182/Blood.V108.11.4730.4730 |
0.512 |
|
| 2006 |
Czuczman MS, Pinter-Brown L, Lechowicz MJ, Bartlett N, Lazarus H, Lister J, Goy A, Kahanic S, Rosen P, Acosta M. Phase II Study of Denileukin Diftitox (ONTAK®) in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL) and Poor Bone Marrow Reserve. Blood. 108: 4724-4724. DOI: 10.1182/Blood.V108.11.4724.4724 |
0.442 |
|
| 2006 |
Chanan-khan AA, Padmanabhan S, Miller KC, Musiel L, Yu J, Bernstein ZP, Manochakian R, Czuczman MS. Final Results of a Phase II Study of Bortezomib (Velcade) in Combination with Liposomal Doxorubicin (Doxil) and Thalidomide (VDT) Demonstrate a Sustained High Response Rates in Patients (pts) with Relapsed (rel) or Refactory (ref) Multiple Myeloma. Blood. 108: 3539-3539. DOI: 10.1182/Blood.V108.11.3539.3539 |
0.448 |
|
| 2006 |
Rodriguez MA, Veer AT, Nademanee A, Niland J, Lepisto E, Kho M, LaCasce A, Weeks JC, Czuczman M, Millenson M, Friedberg J, Zelenetz AD. Concordance with National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (CPGs): A Quality of Care Tool for Newly Diagnosed Patients (pts) with Mantle Cell Lymphoma (MCL). Blood. 108: 3328-3328. DOI: 10.1182/Blood.V108.11.3328.3328 |
0.384 |
|
| 2006 |
Chanan-Khan AA, Miller KC, Musial L, Padmanabhan S, Lawrence D, Bernstein ZP, Takeshita K, Spaner D, Byrne C, Chrystal C, Czuczman MS. Clinical Efficacy of Lenalidomide {Revlimid®} in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase II Clinical Trial. Blood. 108: 306-306. DOI: 10.1182/Blood.V108.11.306.306 |
0.417 |
|
| 2006 |
Fayad L, Patel H, Verhoef G, Czuczman M, Foran J, Gine E, Rohatiner A, Smith MR, Shapiro M, Advani A. Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study. Blood. 108: 2711-2711. DOI: 10.1182/Blood.V108.11.2711.2711 |
0.55 |
|
| 2006 |
Hernandez-Ilizaliturri FJ, Iqbal A, Alam N, Bhat S, Olejniczak S, Knight J, Czuczman MS. Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Decreases DNA Synthesis, Induces Cell Death and Sensitizes Rituximab-Sensitive and Resistant Non-Hodgkin’s Lymphoma Cell Lines to the Anti-Tumor Activity of Chemotherapy Agents. Blood. 108: 2523-2523. DOI: 10.1182/Blood.V108.11.2523.2523 |
0.523 |
|
| 2006 |
Reddy N, Cruz R, Hernandez-Ilizaliturri F, Knight J, Czuczman MS. Lenalidomide (Revlimid®) Enhances Monoclonal Antibody-Associated Anti-Tumor Activity Against Rituximab-Sensitive and Rituximab-Resistant B-Cell Lymphoma Cell Lines. Blood. 108: 2522-2522. DOI: 10.1182/Blood.V108.11.2522.2522 |
0.51 |
|
| 2006 |
Hernandez-Ilizaliturri FJ, Bhat S, Iqbal A, Olejniczak S, Knight J, Czuczman MS. Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Significantly Increases Rituximab-Mediated Antibody Dependent Cellular Cytotoxicity (ADCC) and Complement Mediated Cytotoxicity (CMC) Against B-Cell Lymphomas. Blood. 108: 2502-2502. DOI: 10.1182/Blood.V108.11.2502.2502 |
0.501 |
|
| 2006 |
Ramanarayanan J, Brodzik F, Czuczman MS, Hernandez-Ilizaliturri FJ. Efficacy and Safety of Rituximab in the Treatment of Refractory/Relapsed Idiopathic Thrombocytopenic Purpura (ITP): Results of a Meta-Analysis of 299 Patients. Blood. 108: 1076-1076. DOI: 10.1182/Blood.V108.11.1076.1076 |
0.49 |
|
| 2005 |
Wilson WH, Porcu P, Hurd D, Martin SE, Czuczman M, Niedzwiecki D, Saint Louis JD, Johnson JL, Cheson B, Canellos GP, Zelenetz AD. Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6530. PMID 27943874 DOI: 10.1200/Jco.2005.23.16_Suppl.6530 |
0.483 |
|
| 2005 |
Hernandez-Ilizaliturri FJ, Jupudy V, Reising S, Repasky EA, Czuczman MS. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leukemia & Lymphoma. 46: 1775-84. PMID 16263581 DOI: 10.1080/17402520500182329 |
0.339 |
|
| 2005 |
Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma Leukemia & Lymphoma. 46: 1569-1573. PMID 16236611 DOI: 10.1080/10428190500217312 |
0.512 |
|
| 2005 |
Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5984-92. PMID 16115943 DOI: 10.1158/1078-0432.Ccr-05-0577 |
0.49 |
|
| 2005 |
Chanan-Khan A, Miller KC, Takeshita K, Koryzna A, Donohue K, Bernstein ZP, Mohr A, Klippenstein D, Wallace P, Zeldis JB, Berger C, Czuczman MS. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood. 106: 3348-52. PMID 16051743 DOI: 10.1182/Blood-2005-02-0669 |
0.452 |
|
| 2005 |
Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, Sweetenham J, Alkuzweny B, Finucane DM, Leigh BR. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4390-8. PMID 15994148 DOI: 10.1200/Jco.2005.09.018 |
0.435 |
|
| 2005 |
Shaukat A, Bakri F, Young P, Hahn T, Ball D, Baer MR, Wetzler M, Slack JL, Loud P, Czuczman M, McCarthy PL, Walsh TJ, Segal BH. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia. 159: 181-8. PMID 15770441 DOI: 10.1007/S11046-004-5495-0 |
0.341 |
|
| 2005 |
Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma Journal of Clinical Oncology. 23: 694-704. PMID 15681517 DOI: 10.1200/Jco.2005.02.172 |
0.483 |
|
| 2005 |
Hahn T, Benekli M, Wong C, Moysich KB, Hyland A, Michalek AM, Alam A, Baer MR, Bambach B, Czuczman MS, Wetzler M, Becker JL, McCarthy PL. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplantation. 35: 557-66. PMID 15665852 DOI: 10.1038/sj.bmt.1704789 |
0.303 |
|
| 2005 |
Kansal R, Sait SN, Block AW, Ward PM, Kelly FL, Cheney RT, Czuczman M, Brecher ML, Barcos M. Extra copies of chromosome 2 are a recurring aberration in ALK-negative lymphomas with anaplastic morphology. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 18: 235-43. PMID 15475930 DOI: 10.1038/Modpathol.3800299 |
0.449 |
|
| 2005 |
Miller KC, Czuczman MS, Dimiceli L, McCarthy P, Bernstein ZP, Zeldis JB, Mohr A, Chanan-Khan AA. Antileukemic effects of novel immunomodulatory agent lenalinomide (L) with or without rituximab (R) in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL). Encouraging preliminary results of an ongoing phase II clinical study Journal of Clinical Oncology. 23: 6557-6557. DOI: 10.1200/Jco.2005.23.16_Suppl.6557 |
0.413 |
|
| 2005 |
Younes A, Vose JM, Zelenetz AD, Smith MR, Burris H, Ansell S, Klein J, Kumm E, Czuczman M. Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL). Blood. 106: 489-489. DOI: 10.1182/Blood.V106.11.489.489 |
0.465 |
|
| 2005 |
Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Loss of Expression of the Pro-Apoptotic Bcl-2 Family Proteins Bak and Bax in Rituximab- and Chemotherapy-Resistant Non-Hodgkin’s Lymphoma Cells. Blood. 106: 4819-4819. DOI: 10.1182/Blood.V106.11.4819.4819 |
0.468 |
|
| 2005 |
Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Lack of Lipid Raft Domain Reorganization Following Ligation of CD20 Is Associated with Resistance to Rituximab-Induced Complement-Dependent Cytotoxicity. Blood. 106: 4818-4818. DOI: 10.1182/Blood.V106.11.4818.4818 |
0.461 |
|
| 2005 |
Chanan-Khan AA, Miller KC, DiMiceli L, Padmanabhan S, Lawrence D, Bernstein ZP, Takeshita K, Spaner D, Wallace P, Byrne C, Crystal C, Czuczman MS. Results of Phase II Study of Lenalidomide (L) {Revlimid ® } in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Blood. 106: 447-447. DOI: 10.1182/Blood.V106.11.447.447 |
0.393 |
|
| 2005 |
Chanan-Khan AA, Miller KC, Marshall P, Padmanabhan S, Brady W, Bernstein ZP, Wallace P, Czuczman MS. Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Preliminary Results of a Phase I/II Clinical Trial. Blood. 106: 2974-2974. DOI: 10.1182/Blood.V106.11.2974.2974 |
0.417 |
|
| 2005 |
LaCasce A, Niland J, Kho ME, terVeer A, Friedberg JW, Rodriguez MA, Czuczman MS, Millenson M, Zelenetz AD, Nademanee AP, Weeks JC. Potential Impact of Pathologic Review on Therapy in Non-Hodgkin’s Lymphoma (NHL): Analysis from the National Comprehensive Cancer Network (NCCN) NHL Outcomes Project. Blood. 106: 2816-2816. DOI: 10.1182/Blood.V106.11.2816.2816 |
0.438 |
|
| 2005 |
Friedberg JW, Leonard JP, Younes A, Fisher DC, Gordon LI, Moore JO, Czuczman MS, Miller TP, Stiff PJ, Cheson BD, Forero-Torres A, Finucane DM, Leigh BR, Molina A. Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL. Blood. 106: 2435-2435. DOI: 10.1182/Blood.V106.11.2435.2435 |
0.444 |
|
| 2005 |
Czuczman MS, Maddipatla S, Knight J, Hernandez-Ilizaliturri FJ. In Vitro Synergistic Anti-Tumor Activity by Targeting TRAIL-R1 and CD20 Antigen by Combining HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) and Rituximab Monoclonal Antibody Against Non-Hodgkin’s Lymphoma Cells (NHL). Blood. 106: 1475-1475. DOI: 10.1182/Blood.V106.11.1475.1475 |
0.451 |
|
| 2005 |
Hernandez-Ilizaliturri FJ, Olejniczak SH, Knight J, Czuczman MS. Structural Changes in the Internal Domain of CD20 Antigen Associated with the Emergence of Rituximab Resistance: Effects of Proteasome Inhibition in CD20 Structure and Rituximab Anti-Tumor Activity in Rituximab-Resistant Cell Lines (RRCL). Blood. 106: 1474-1474. DOI: 10.1182/Blood.V106.11.1474.1474 |
0.382 |
|
| 2005 |
Hernandez-Ilizaliturri FJ, Devineni S, Arora S, Knight J, Czuczman MS. Targeting CD20 and CD22 with Rituximab in Combination with CMC-544 Results in Improved Anti-Tumor Activity Against Non-Hodgkin’s Lymphoma (NHL) Pre-Clinical Models. Blood. 106: 1473-1473. DOI: 10.1182/Blood.V106.11.1473.1473 |
0.501 |
|
| 2005 |
Rodriguez MA, Czuczman MS, Friedberg JW, Kho ME, LaCasce AS, Millenson M, Auayporn N, Niland J, Veer AT, Zelenetz AD, Weeks JC. Age Significantly Influences Presentation and Patterns of Care in Patients with Newly Diagnosed Diffuse Large Cell Lymphoma (DLCL): Collective Data from 5 Centers Participating in the National Comprehensive Center Network (NCCN) NHL Outcomes Project. Blood. 106: 1335-1335. DOI: 10.1182/Blood.V106.11.1335.1335 |
0.391 |
|
| 2004 |
Scarpace SL, Miller K, Elefante A, Czuczman MS, McCarthy P, Chanan-Khan A. Cost-utility of darbepoetin alfa (DARBE) on an every-2 week (QOW) schedule in anemic non-myeloid hematologic malignancies: A positive overall impact on the healthcare system (HCS). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 8278. PMID 28016739 DOI: 10.1200/Jco.2004.22.14_Suppl.8278 |
0.306 |
|
| 2004 |
Reddy NM, Hernandez-Ilizaliturri FJ, Czuczman MS. The role of natural killer (NK) cell expansion and activation on the in vivo anti-tumor activity of immunomodulatory drug (IMiD) CC4047 plus rituximab in a severe combined immunodeficiency (SCID) lymphoma mouse model. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2556. PMID 28015257 DOI: 10.1200/Jco.2004.22.14_Suppl.2556 |
0.393 |
|
| 2004 |
Gowda AC, Hernandez-Ilizaliturri FJ, Connolly G, Czuczman MS. Structural changes in the internal domain of the CD20 antigen is associated with the development of rituximab resistance: Effects on signaling and redistribution of CD20 into lipid raft domains in rituximab-resistant cell lines (RRCL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2502. PMID 28015007 DOI: 10.1200/Jco.2004.22.14_Suppl.2502 |
0.398 |
|
| 2004 |
Hernandez-Ilizaliturri FJ, Gowda A, Czuczman MS. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma. Clinical Advances in Hematology & Oncology : H&O. 2: 606-18. PMID 16163245 |
0.428 |
|
| 2004 |
Ansell SM, Schilder RJ, Pieslor PC, Gordon LI, Emmanouilides C, Vo K, Czuczman MS, Witzig TE, Theuer C, Molina A. Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Clinical Lymphoma. 5: 202-4. PMID 15636698 DOI: 10.3816/Clm.2004.N.028 |
0.472 |
|
| 2004 |
Hahn T, Alam AR, Lawrence D, Ford L, Baer MR, Bambach B, Bernstein ZP, Czuczman MS, Silva J, Slack JL, Wetzler M, Becker J, McCarthy PL. Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion Transplantation. 78: 1515-1522. PMID 15599317 DOI: 10.1097/01.Tp.0000141363.81600.0D |
0.311 |
|
| 2004 |
Ramanarayanan J, Hernandez-Ilizaliturri FJ, Chanan-Khan A, Czuczman MS. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. British Journal of Haematology. 127: 519-30. PMID 15566355 DOI: 10.1111/J.1365-2141.2004.05239.X |
0.447 |
|
| 2004 |
Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-López AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4711-6. PMID 15483015 DOI: 10.1200/Jco.2004.04.020 |
0.528 |
|
| 2004 |
Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, Vo K, Theuer C, Pohlman B, Bartlett N, Wiseman G, Darif M, White C. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clinical Lymphoma. 5: 98-101. PMID 15453924 DOI: 10.3816/Clm.2004.N.015 |
0.482 |
|
| 2004 |
Chanan-Khan A, Islam T, Alam A, Miller KC, Gibbs J, Barcos M, Czuczman MS, Paplham P, Hahn T, McCarthy P. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma. Leukemia & Lymphoma. 45: 1673-5. PMID 15370223 DOI: 10.1080/10428190310001609924 |
0.488 |
|
| 2004 |
Srinivasan S, Takeshita K, Holkova B, Czuczman MS, Miller K, Bernstein ZP, Driscoll D, Chanan-Khan A. Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-ARL) and the impact of HAART. Hiv Clinical Trials. 5: 140-5. PMID 15248138 DOI: 10.1310/Bdhx-D9Bc-Ywvu-9Nbr |
0.414 |
|
| 2004 |
Chanan-Khan A, Czuczman MS. Bcl-2 antisense therapy in B-cell malignant proliferative disorders. Current Treatment Options in Oncology. 5: 261-7. PMID 15233903 DOI: 10.1007/S11864-004-0017-3 |
0.517 |
|
| 2004 |
Emmanouilides C, Czuczman MS, Revell S, Witzig TE, Wang H, Gordon LI, Skikne B, Foster P, Molina A. Low incidence of treatment-related myelodysplastic syndrome (tMDS) and acute myelogenous leukemia (tAML) in patients with non-Hodgkin's lymphoma (NHL) treated with ibritumomab tiuxetan Journal of Clinical Oncology. 22: 6696-6696. DOI: 10.1200/Jco.2004.22.90140.6696 |
0.426 |
|
| 2004 |
Ramanarayanan J, Hernandez-Ilizaliturri FJ, Czuczman MS. Oblimersen sodium (G3139) targeting bcl-2 mRNA overcomes acquired resistance to rituximab and sensitizes rituximab-resistant non-Hodgkin's lymphoma (NHL) cells to rituximab-associated complement mediated cytotoxicity (CMC) and antibody dependant cellular cytotoxicity (ADCC) Journal of Clinical Oncology. 22: 3180-3180. DOI: 10.1200/Jco.2004.22.14_Suppl.3180 |
0.436 |
|
| 2004 |
Hernandez FJ, Reddy N, Nallapareddy S, Czuczman MS. Biological Effects of Rabbit Anti-Thymocyte Immunoglobulin (rATG, Thymoglobulin®) in T-Cell Non-Hodgkin’s Lymphoma Cell Lines. Blood. 104: 4628-4628. DOI: 10.1182/Blood.V104.11.4628.4628 |
0.474 |
|
| 2004 |
Chanan-Khan AA, Miller K, Koryzna A, Takeshita K, McCarthy P, Mohr A, Donohue K, Bernstein ZP, Alam A, Czuczman MS. Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial. Blood. 104: 3476-3476. DOI: 10.1182/Blood.V104.11.3476.3476 |
0.375 |
|
| 2004 |
Chanan-Khan AA, Miller KC, McCarthy P, Koryzna A, Kouides P, Donohue K, Mohr A, Bernstein ZP, Alam A, Czuczman MS. VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM). Blood. 104: 3463-3463. DOI: 10.1182/Blood.V104.11.3463.3463 |
0.428 |
|
| 2004 |
Czuczman M, Leigh BR, Witzig TE, Vose JM, Younes A, Alkuzweny B, Larocca A, Cao X, Thall A. Fc-Gamma Receptor IIIa and Interferon-Gamma SNPs Do Not Predict Responsiveness of Follicular Lymphoma to Galiximab (Anti-CD80 Antibody). Blood. 104: 3292-3292. DOI: 10.1182/Blood.V104.11.3292.3292 |
0.386 |
|
| 2004 |
Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Canellos GP, Cheson BD. CALGB 59901: Results of a Phase II Study of 506U78 in CTCL and PTCL. Blood. 104: 2486-2486. DOI: 10.1182/Blood.V104.11.2486.2486 |
0.438 |
|
| 2004 |
Chanan-Khan AA, Miller KC, McCarthy P, DiMiceli LA, Yu J, Bernstein ZP, Czuczman MS. A Phase II Study of Velcade (V), Doxil (D) in Combination with Low-Dose Thalidomide (T) as Salvage Therapy for Patients (pts) with Relapsed (rel) or Refractory (ref) Multiple Myeloma (MM) and Waldenstorm Macroglobulinemia (WM): Encouraging Preliminary Results. Blood. 104: 2421-2421. DOI: 10.1182/Blood.V104.11.2421.2421 |
0.406 |
|
| 2004 |
Olejniczak SH, Hernandez FJ, Czuczman MS. Acquirement of Rituximab Resistance Is Associated with the Development of Chemotherapy Resistance in B-Cell Lymphoma Cells: Evidence of Shared Pathways of Resistance between Chemotherapeutic Agents and Biological Therapies. Blood. 104: 2297-2297. DOI: 10.1182/Blood.V104.11.2297.2297 |
0.512 |
|
| 2004 |
Hernandez-Ilizaliturri FJ, Gowda AC, Brombos D, Spear D, Czuczman MS. The Effects of Alemtuzumab (A) Dose-Sequence upon Rituximab (R)-Induced Reorganization of Lipid Raft Domains and In-Vitro/In Vivo Anti-Tumor Activity. Blood. 104: 2289-2289. DOI: 10.1182/Blood.V104.11.2289.2289 |
0.452 |
|
| 2004 |
Czuczman MS, Olejniczak S, Gowda AC, Starostik P, Hernandez-Ilizaliturri FJ. Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Structural Changes in the Internal Domain of CD20 Regulated at the Post-Transcriptional Level. Blood. 104: 2280-2280. DOI: 10.1182/Blood.V104.11.2280.2280 |
0.376 |
|
| 2004 |
Ramanarayanan J, Hernandez-Ilizaliturri FJ, Czuczman MS. In Vivo Downregulation of Bcl-2 by G3139 (G) Enhances Rituximab (R) Anti-Tumor Activity: Effect of Sequential Versus Concurrent G3139 Administration on Survival in a Lymphoma-Bearing SCID Mouse Model. Blood. 104: 1398-1398. DOI: 10.1182/Blood.V104.11.1398.1398 |
0.363 |
|
| 2004 |
Czuczman MS, Skipper M, Mohr A, Bernstein ZP, McCarthy P, Hernandez-Ilizaliturri F, Chanan-Khan AA. Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results. Blood. 104: 1396-1396. DOI: 10.1182/Blood.V104.11.1396.1396 |
0.476 |
|
| 2004 |
Friedberg JW, Kho ME, Lepisto EM, Rodriguez MA, TerVeer A, LaCasce AS, Nademanee AP, Millenson M, Czuczman M, Niland J, Zelenetz AD, Weeks JC. Evolution of Rituximab as “Standard” Therapy in Patients (pts) with Newly Diagnosed Follicular (FL), Mantle Cell (MCL), and Diffuse Large B Cell (DLCL) Non-Hodgkin’s Lymphoma (NHL) in 5 United States Comprehensive Cancer Centers: An Analysis from the National Comprehensive Cancer Network (NCCN) NHL Outcomes Project. Blood. 104: 1391-1391. DOI: 10.1182/Blood.V104.11.1391.1391 |
0.375 |
|
| 2003 |
Czuczman M, Zinzani PL. The first International Workshop on Non-Hodgkin's Lymphoma: taking a close look at current issues and future developments. Leukemia & Lymphoma. 44. PMID 15202518 DOI: 10.1080/10428190310001621579 |
0.319 |
|
| 2003 |
Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5866-73. PMID 14676108 |
0.341 |
|
| 2003 |
Hahn T, Wolff SN, Czuczman M, Fisher RI, Lazarus HM, McCarthy PL, Vose J, Warren L, Watt R. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin's lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 9: 667. PMID 14569563 DOI: 10.1016/J.Bbmt.2003.09.012 |
0.43 |
|
| 2003 |
Benekli M, Hahn T, Shafi F, Qureshi A, Alam AR, Czuczman MS, Bernstein ZP, Chanan-Khan AA, Becker JL, McCarthy PL. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients Bone Marrow Transplantation. 32: 139-143. PMID 12838277 DOI: 10.1038/Sj.Bmt.1704106 |
0.457 |
|
| 2002 |
Gordon LI, Witzig TE, Wiseman GA, Flinn IW, Spies SS, Silverman DH, Emmanuolides C, Cripe L, Saleh M, Czuczman MS, Olejnik T, White CA, Grillo-López AJ. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Seminars in Oncology. 29: 87-92. PMID 28140097 DOI: 10.1053/Sonc.2002.30148 |
0.451 |
|
| 2002 |
Imrie KR, Linch DC, Czuczman MS. Debate on the conservative and aggressive treatment options for the optimal management of indolent non-Hodgkin's lymphoma Anti-Cancer Drugs. 13. PMID 12710587 |
0.375 |
|
| 2002 |
Hagenbeek A, Czuczman MS, Ghielmini M, Herold M, Kimby E, Solal-Céligny P, Unterhalt M. Rituximab therapy for indolent non-Hodgkin's lymphoma Anti-Cancer Drugs. 13. PMID 12710586 DOI: 10.1097/00001813-200211002-00003 |
0.535 |
|
| 2002 |
Lamonica D, Czuczman M, Nabi H, Klippenstein D, Grossman Z. Radioimmunoscintigraphy (RIS) with bectumomab (Tc99m labeled IMMU-LL2, Lymphoscan) in the assessment of recurrent non-Hodgkin's lymphoma (NHL). Cancer Biotherapy & Radiopharmaceuticals. 17: 689-97. PMID 12537673 DOI: 10.1089/108497802320970307 |
0.364 |
|
| 2002 |
Chanan-Khan A, Czuczman MS. Radioimmunotherapy in non-Hodgkin lymphoma Current Opinion in Oncology. 14: 484-489. PMID 12192266 DOI: 10.1097/00001622-200209000-00003 |
0.438 |
|
| 2002 |
Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 3262-9. PMID 12149300 DOI: 10.1200/Jco.2002.11.017 |
0.473 |
|
| 2002 |
Czuczman MS. Immunochemotherapy in indolent non-Hodgkin's lymphoma Seminars in Oncology. 29: 11-17. PMID 12040529 DOI: 10.1053/Sonc.2002.32748 |
0.563 |
|
| 2002 |
Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma Journal of Clinical Oncology. 20: 2453-2463. PMID 12011122 DOI: 10.1200/Jco.2002.11.076 |
0.477 |
|
| 2002 |
Gordon LI, Witzig TE, Wiseman GA, Flinn IW, Spies SS, Silverman DH, Emmanouilides C, Cripe L, Saleh M, Czuczman MS, Olejnik T, White CA, Grillo-López AJ, Emmanuolides C. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Seminars in Oncology. 29: 87-92. PMID 11842394 |
0.338 |
|
| 2002 |
Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-López AJ, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma Seminars in Oncology. 29: 36-40. PMID 11842387 DOI: 10.1053/Sonc.2002.30152 |
0.519 |
|
| 2001 |
Czuczman MS. Combination chemotherapy and rituximab Anti-Cancer Drugs. 12. PMID 11508932 |
0.428 |
|
| 2001 |
Hahn T, Wolff SN, Czuczman M, Fisher RI, Lazarus HM, Vose JM, Warren L, Watt R, McCartby PL. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: An evidence-based review Biology of Blood and Marrow Transplantation. 7: 308-331. PMID 11464975 DOI: 10.1016/S1083-8791(01)80003-3 |
0.416 |
|
| 2001 |
Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma Leukemia and Lymphoma. 41: 77-87. PMID 11342359 DOI: 10.3109/10428190109057956 |
0.486 |
|
| 2001 |
Czuczman MS, Grillo-López AJ, McLaughlin P, White CA, Saleh M, Gordon L, LoBuglio AF, Rosenberg J, Alkuzweny B, Maloney D. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy Annals of Oncology. 12: 109-114. PMID 11249036 DOI: 10.1023/A:1008395214584 |
0.492 |
|
| 2001 |
Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 389-97. PMID 11208830 DOI: 10.1200/JCO.2001.19.2.389 |
0.395 |
|
| 2000 |
Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment Journal of Clinical Oncology. 18: 3135-3143. PMID 10963642 DOI: 10.1200/Jco.2000.18.17.3135 |
0.495 |
|
| 2000 |
Witzig TE, Gordon LI, Leigh BR, Wiseman GA, Emmanouilides C, Czuczman MS, Murray JL, Zhang C, Grillo-Lopez AJ, White CA. Baseline peripheral blood B-cell levels correlate with disease-free interval and response to zevalin radioimmunotherapy of relapsed non-hodgkin's lymphoma Blood. 96. |
0.458 |
|
| 2000 |
Wiseman GA, Gordon LI, Witzig TE, Spies S, Murray JL, Bartlett NL, Flinn IW, Czuczman MS, Emmanouilides C, Rosenberg J, Multani PS, Grillo-López AJ, White CA. Zevalin radioimmunotherapy is not associated with significant or prolonged depletion of t cells or natural killer cells Blood. 96. |
0.346 |
|
| 1999 |
Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma Seminars in Oncology. 26: 88-96. PMID 10561023 |
0.463 |
|
| 1999 |
Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy Journal of Clinical Oncology. 17: 268-276. PMID 10458242 DOI: 10.1200/Jco.1999.17.1.268 |
0.542 |
|
| 1999 |
Piro LD, White CA, Grillo-López AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolit JE, Jain V. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma Annals of Oncology. 10: 655-661. PMID 10442187 DOI: 10.1023/A:1008389119525 |
0.571 |
|
| 1999 |
Czuczman MS, Dodge RK, Stewart CC, Frankel SR, Davey FR, Powell BL, Szatrowski TP, Schiffer CA, Larson RA, Bloomfield CD. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood. 93: 3931-9. PMID 10339502 DOI: 10.1182/Blood.V93.11.3931.411A30_3931_3939 |
0.427 |
|
| 1999 |
Berinstein NL, Grillo-López AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 9: 995-1001. PMID 9818074 DOI: 10.1023/A:1008416911099 |
0.451 |
|
| 1999 |
Czuczman MS. Rituximab Drugs. 58: 89-90. DOI: 10.2165/00003495-199958010-00010 |
0.345 |
|
| 1998 |
Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody Current Opinion in Oncology. 10: 548-551. PMID 9818234 DOI: 10.1097/00001622-199811000-00012 |
0.48 |
|
| 1998 |
McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 2825-33. PMID 9704735 DOI: 10.1200/Jco.1998.16.8.2825 |
0.486 |
|
| 1997 |
Czuczman M, Grillo-Ló;pez AJ, White CA, Saleh M, Gordon L, Lobuglio AF, Jonas C, Shen D, Burris K, Dallaire BK, Royston I. RITUXANTM/CHOP CHEMO IMMUNOTHERAPY IN PATIENTS WITH LOW-GRADE OR FOLLICULAR (LG/F) NON-HODGKINʼS LYMPHOMA (NHL) Journal of Immunotherapy. 20: 401. DOI: 10.1097/00002371-199709000-00018 |
0.374 |
|
| 1997 |
White CA, Grillo-López AJ, Maloney D, Bodkin D, Czuczman M, McLaughlin P, Cabanillas F, Saven A, Saleh M. Review of single agent IDEC-C2B8 safety and efficacy results in low-grade or follicular non-Hodgkin's lymphoma (NHL) European Journal of Cancer. 33. DOI: 10.1016/S0959-8049(97)89438-5 |
0.371 |
|
| 1994 |
Czuczman MS, Nabi HA, Meredith RM, Blend M, Riva P, Hughes L, Sharkey RM, Goldenberg DM. Radioimmunotherapy Of B-Cell Lymphomas With Iodine-131-Labeled Ll2 Monoclonal Antibody Journal of Immunotherapy. 16: 160. DOI: 10.1097/00002371-199408000-00057 |
0.394 |
|
| 1993 |
Czuczman MS, Garin-Chesa P, Lemoli RM, Scheinberg DA. IgM monoclonal antibody JD118 recognizes an inducible antigen target for human-complement-mediated cytotoxicity against neoplastic B cells Cancer Immunology Immunotherapy. 36: 387-396. PMID 8500111 DOI: 10.1007/Bf01742255 |
0.429 |
|
| 1993 |
Czuczman MS, Straus DJ, Divgi CR, Graham M, Garin-Chesa P, Finn R, Myers J, Old LJ, Larson SM, Scheinberg DA. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-hodgkin's lymphoma Journal of Clinical Oncology. 11: 2021-2029. PMID 8410126 DOI: 10.1200/Jco.1993.11.10.2021 |
0.452 |
|
| Show low-probability matches. |